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Abstract 
 
Neuroinflammation is a pathophysiological process present in a number of neurodegenerative 
disorders, including following acute insults such as stroke, traumatic brain injury including 
chronic traumatic encephalopathy as well as age-related CNS disorders such as Huntington’s 
disease, Parkinson’s disease and Alzheimer’s disease (AD). Although there is still much debate 
over the initial trigger for these neurodegenerative disorders, neuroinflammation appears to be a 
major contributor, and therefore anti-inflammatory drugs including cytokine suppressive anti-
inflammatory drugs (CSAIDs) might be promising therapeutic options to limit 
neuroinflammation, neurodegeneration and therefore improve the clinical outcome. One of the 
most promising CSAIDs is curcumin, which modulates the activity of several transcription 
factors (e.g., STAT, NF-κB, AP-1), most likely by interfering with upstream pro-inflammatory 
signaling pathways. Curcumin is a potent CSAID, but is not soluble in water and oily solvents 
like other polyphenols but soluble in methanol and ethanol, and degrades at low PH, it has low 
solubility and bioavailability in vivo. In order to increase its bioavailability, a variety of curcumin 
preparations have been designed, which lead to increased bioavailability, with the goal to 
achieve therapeutic concentrations in the brain.  
The aim of this thesis was to investigate the effect of two different formulations of curcumin, 
Meriva curcumin phytosome (MCP) and Longvida curcumin (LC) in GFAP-IL6 mice, a model 
of chronic microglial activation. MCP preparations were fed for short term (one month) in three 
doses (140mg/kg bw, 70mg/kg bw and 35mg/kg bw whereas LC was fed long term (6 months) at 
a dose of 500ppm. 
The following chapters will display the experiments undertaken to investigate the anti-
inflammatory effects of these two curcumin formulations in the brain 
The first experimental chapter focused on the effect of MCP on microglial and astroglial cells 
using stereology. The hippocampus of GFAP-IL6 mice fed with normal food had 438,550 ± 
29,717 Iba-1+ microglia, 147,803 ± 46,723 TSPO+ microglia and 530,374 ± 30,447 GFAP+ 
astrocytes, which was significantly higher than that of the WT mice [(175,192 ± 12,098), (474,7 
± 386,6), (169,908 ± 17,046)]. In the cerebellum, GPAP-IL6 mice had 1025,205 ± 104,467 Iba-
1+ microglia and 369,963 ± 152,991 TSPO+ microglia, which was significantly higher than that 
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of WT mice [(154,058 ± 12,871), (12,402 ± 8,820)]. The main outcome was, all three doses of 
MCP significantly reduced the number of Iba-1+ microglia in the cerebellum and the 
hippocampus and GFAP+ astrocytes in the hippocampus with the high dose of MCP resulting in 
the most significant decrease.  
The second experimental chapter investigated the effect of MCP on the morphology of 
microglial and astroglial cells. In the hippocampus, the Iba-1+ microglial cells of GFAP-IL6 
mice had significantly larger soma areas (66.36 ± 22.63µm2), soma perimeters (33.93 ± 8.18µm)  
and more processes (5.62 ± 1.84)  than those of WT mice [soma area (30.005 ± 13.93µm2), soma 
perimeter (20.63 ± 5.50µm) and number of processes (3.66 ± 1.36)]. Whereas, in the cerebellum, 
microglial cells of GFAP-IL6 mice fed with normal food displayed significantly larger soma 
areas (66.64 ± 12.62) and soma perimeters (33.3 ± 2.84)  as compared to those of WT mice 
[microglial soma area (30.03 ± 8.64) and soma perimeter (20.55 ± 0.28)]. The astrocytes in the 
GFAP-IL6 normal food fed mice had significantly larger convex area (1247.74 ± 371.77µm2), 
convex perimeter (142.27 ± 26.27µm), dendritic length (224.35 ± 66.24µm), and number of 
nodes (7.33 ± 2.49), when compared to astrocytes of WT mice [convex area (601.93 ± 201.46 
µm2), convex perimeter (95.04 ± 27.79 µm), dendritic length (107.68 ± 29.17 µm) and number 
of nodes (4.68 ± 1.0)]. The key finding was that the 140mg/kg dose of MCP significantly 
reduced the de-ramification and aggregation of microglial cells in GFAP-IL6 mice. In addition, 
the high and medium dose of MCP significantly decreased the dendritic length of activated 
astrocytes in the hippocampus and reversed the astrocytes activation. The third and fourth 
experimental chapters focused on the impact of long term feeding of LC on microglial and 
astroglial cells stereology and morphology. The hippocampus of WT mice fed with normal food 
had 184,706 ± 19,037 Iba-1+ microglia, 6,626 ± 3,952 TSPO+ microglia and 211,968 ± 11,730 
GFAP+ astrocytes which was significantly increased in GFAP-IL6 mice normal food fed mice 
[383,588 ± 12,253 Iba-1+ microglia, 236, 098 ± 28,005 TSPO+ microglia and GFAP+ astrocytes 
]. Whereas, in cerebellum, the wild type mice had 156,454 ± 33,721 Iba-1+ microglia and 18,108 
± 2,933 TSPO+ microglia, which was significantly increased in GFAP-IL6 mice [847,456 ± 
46,120 Iba-1+ microglia, 364,942 ± 28,577 TSPO+ microglia]. The key findings were that LC 
significantly reduced Iba-1+ microglia and GFAP+ astrocytes the hippocampus while it slightly 
reduced the Iba-1+ microglia in the cerebellum and TSPO+ microglia in both cerebellum and 
hippocampus. Furthermore, in the hippocampus, Iba-1+ microglial cells of normal fed GFAP-IL6 
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mice had significantly larger soma areas (57.25 ± 4.03µm2), small convex areas (1035.60 ± 
79.12µm2)  and convex perimeter (127.68 ± 4.39µm) than those of WT [soma areas (42.57 ± 
3.82µm2), convex areas (1535.63 ± 139.68µm2) and convex perimeter (155.83 ± 6.11µm)]. 
Similarly, in cerebellum, Iba-1+ microglial cells of GFAP-IL6 mice normal fed had significantly 
large soma area (77.68±7.89µm2), soma perimeter (37.21±2.44µm) and small convex area 
(1087.96±150µm2), convex perimeter (137.57±9.45µm) (p < 0.026) than those of the wild type 
non-fed mice [soma area (38.82 ± 2.80µm2), soma perimeter (24.10 ± 0.82µm) and small convex 
area (1750.71 ± 148.98µm2), convex perimeter (171.42 ± 7.98µm). Also, the astrocytes in the 
GFAP-IL6 normal-diet mice had a significantly larger dendritic length (275 ± 17.8µm), a 
number of processes (6.06 ± 0.51), convex area (1418 ± 128.3µm2), convex perimeter (147.9 ± 
6.01µm) and a number of nodes (7.62 ± 0.77) compared to the wild types. The LC significantly 
downregulated some of the morphological features of activated microglia and astrocytes and 
reversed the activation of both. Overall, our results suggest that the high dose MCP and LC 
formulation have the potential to overcome the chronic neuroinflammation and glial cells 
activation in GFAP-IL6 mice. 
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1. General Introduction 
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1.1. Neuroinflammation and neuroinflammatory cytokines 
 
Inflammation is a protective reponse of the living tissues to injury, foreign bodies or trauma. 
Neuroinflammation is triggered by the activation of microglia and astrocytes that ultimately 
produce pro-inflammatory cytokines and neurotoxic factors, such as reactive oxidative species 
(ROS) leading to neuronal damage and the subsequent cognitive deficits (Agostinho, Cunha, and 
Oliveira 2010; Dantzer et al. 2008). Therefore, pro-inflammatory cytokines and oxidative stress 
could be associated with memory impairment and other cognitive deficits as manifested by 
neurodegenerative disorders like dementia and AD (Guerreiro et al. 2007).   
Chronic neuroinflammation is now thought to be one the cause of AD, the most common 
neurodegenerative disease, characterized by senile plaques composed of amyloid-β (Aβ) peptide, 
neurofibrillary tangles, neuronal loss and neuroinflammation (Walsh and Selkoe 2004). 
Amyloid-β (Aβ) deposition in the brain and amyloid-β induced oxidative stress have been 
considered to play a vital role in AD pathogenesis (Swomley and Butterfield 2015; Walsh et al. 
2002; Walsh and Selkoe 2004), but it has become more and more doubtful whether Aβ plaques 
and neurofibrillary tangles are actually causative factors for AD or biomarkers of a stressed and 
diseased brain. Recent studies have demonstrated that Aβ plaques accumulation in the brain 
poorly correlates with the progression and severity of dementia in AD (Davis and Laroche 2003). 
Moreover, studies on transgenic animals (APP mutated) showed widespread Aβ plaque 
deposition in the brain but only slight cognitive deficits in these mice (Braak and Braak 1998; 
Davis and Laroche 2003). 
A number of studies of post-mortem human brain tissue have reported that the activation of the 
inflammatory processes such as activated microglia and astrocytes is also observed early stages 
of  AD patients (Akiyama et al. 2000; Meda et al. 1995). Upon activation, microglia cells secrete 
various inflammatory mediators including cytokines such as tumor necrosis factor (TNF), 
interleukin (IL)-1β, IL-α, IL-6 and chemokines that promote the inflammatory state. Since 
inflammation is a defense mechanism, it activates the microglia and may enhance the amyloid β 
clearance (Meda, Baron, and Scarlato 2001; Morgan et al. 2014). However, various 
inflammatory mediators such as IL-1β, IL-6, and TNFα released upon activation of microglia 
may lead to brain damage (Meda, Baron, and Scarlato 2001; Tan and Seshadri 2010). Under 
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normal conditions, this process is monitored by immune cells which are recruited to the 
inflammatory site and remove the external stimulus/pathogen with subsequent resolution of the 
inflammatory response. In neurodegenerative diseases like AD, Aβ deposition and 
neurofibrillary tangles containing hyper-phosphorylated tau protein dysregulate this immune 
process. As a result, the recruited microglia and astrocytes are unable to clear the deposited Aβ 
within the inflammation site but to initiate excessive production of pro-inflammatory cytokines 
and chemokines (Heneka et al. 2015; Heneka, Kummer, and Latz 2014). Recent studies further 
supported the link between AD and the inflammatory state which is characterized by an 
increased level of cytokines (IL-1β, IL-6, TNF-α, TGF-β, and IL-18) in the peripheral blood 
stream (Swardfager et al. 2010). He P et al studied the effect of tumor necrosis factor receptor 1 
(TNFR1) in APP23 transgenic mice and confirmed that the deletion of TNFR1 in APP23 
transgenic mice leads to decrease in Aβ level in the brain and amelioration of cognitive deficits 
(He et al. 2007). Similarly, cytokines like IL-1α and IL-1β increase the APP level-up to 6-folds 
in primary human astrocytes and to 15-fold in human astrocytoma cells (Rogers et al. 1999). 
Cytokines are small (~5–20 kDa) secreted proteins by diverse types of immune cells like 
monocytes and macrophages (microglia and astrocytes) at the sites of inflammation. The key 
functions of cytokines are the regulation of T-cell differentiation, cell proliferation, and 
responses against inflammation and T-cell differentiation from undifferentiated cells (Steinman 
2007). Interleukins (ILs), TNFs, interferons (IFNs), colony stimulating factors (CSFs), and 
certain growth factors are in the same class of these regulatory proteins (Meager 2004). The 
activated macrophages produce pro-inflammatory cytokines that are involved in inflammatory 
responses (Zhang and An 2007). Similarly, activated astrocytes also produce pro-inflammatory 
cytokines and ROS intermediates in the central nervous system (Farina, Aloisi, and Meinl 2007; 
Hirsch and Hunot 2009). In stress conditions induced by microbial infection, a systemic body 
response is activated, which helps to fight against microbial invasion. This systemic response is 
characterized by pyrexia, leukocytosis, and changes in the balance of various proteins in the 
body. The most prominent pro-inflammatory cytokines produced to counteract the infections are 
TNF-α, IL-1β, and IL-6 (Gabay and Kushner 1999). IL-4, IL-10, IL-11, IL-13, and IL-1 receptor 
antagonists act as anti-inflammatory cytokines, whereas IL-6 and some of the growth factors are 
included in either anti-inflammatory or pro-inflammatory class of cytokines. 
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1.2. The role of microglia in neuroinflammation 
 
Microglia demonstrate a certain population of the immune cells, found extensively in the CNS 
(Kettenmann, Kirchhoff, and Verkhratsky 2013). Apart from surveillance of the brain 
microenvironment, recent studies in microglial functions have found that microglia helps in the 
formation of synapses (Paolicelli et al. 2011), regulates neurogenesis (Sierra et al. 2010) and 
contains receptors which respond to different neuronal assaults and help to maintain the 
homeostasis (Pocock and Kettenmann 2007). Under normal physiological conditions, microglia 
were designated “resting” while the reactive morphology was termed “activated.” In normal 
situations, microglial shows delicate branched processes oriented radially to a small elliptical 
soma. In diseased tissue, microglias appear quite different, with enlarged cell bodies, shortened 
and fewer processes and, a phagocytic appearance. Exposure of microglial cells in vitro to 
stimuli such as apoptotic cells, lipopolysaccharide, inflammatory cytokines or aggregated 
proteinsm, retract processes and, in response to appropriate stimuli, secreted factors typical of 
polarized macrophages (Ransohoff 2016).  Ionized calcium binding adaptor molecule 1 (Iba1) is 
a microglial cell specific marker. It binds to fimbrin and helps to participate in membrane 
ruffling and phagocytosis in activated microglia (Ohsawa et al. 2004). Also, the mitochondrial 
translocator protein 18 kDa (TSPO) protein is observed to be expressed in the activated 
microglia (Betlazar et al. 2018). Numerous studies have shown that TSPO in the mitochondria of 
microglia is upregulated upon injury or progressive disease. However, it has long been reported 
that a low-level TSPO expression also occurs in the normal healthy (Liu et al. 2014). 
Neuroinflammation or aging may lead to changes in microglial number and morphology which 
often results in a decrease in microglial ability to respond to neuronal threats (Hefendehl et al. 
2014). Therefore, different types of methods have been used to estimate their numbers. One of 
the studies used Smith and Guttman demonstrated a stereological method for estimating total 
length (L) and total length density (LV) on random intersections with a two‐dimensional 
sampling probe for linear objects in arbitrary tissue sections, found that microglia number in the 
hippocampus increased with age in female WT mice (Mouton et al. 2002). A recent study 
performed on chronic neuroinflammation mouse model (GFAP-IL6) and WT mice in our lab 
used stereological investigator (MBF) to investigate the microglial number. The study found that 
the microglial number significantly increased in the cerebellum region in four different age 
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groups (3,6,14 and 22 months) in GFAP-IL6 mice compared to WT mice using unbiased 
stereology (Gyengesi et al. 2019).   
In situations of neuroinflammation or after injury, a stepwise activation and de-ramification of 
microglia have been observed (Davis, Foster, and Thomas 1994). The morphology of microglia 
is considered one of its major characteristics. According to several studies, the morphology of 
the microglia is not the same through the brain but they have different morphological shapes 
according to the areas in the brain.  Moreover, one study has reported that the morphology of 
microglial cells was ramified in all cerebellar lobules of both young and adult mice but showed 
different sizes and ramification patterns in the different histological layers (Vela et al. 1995). 
Therefore, they have been classified into three subgroup compact, longitudinally branched and 
radially branched (Lawson et al. 1990).  Several studies have reported that changes to the 
microenvironment of the brain, stress, injury to the brain and neuroinflammation can affect the 
structural remodeling of the ramified microglia (Tremblay, Lowery, and Majewska 2010). A 
recent study has suggested that microglia adopt different morphological structural characteristics 
after injury compared to the uninjured brain (Yamada and Jinno 2013). In normal circumstances, 
the resting microglia are characterized by small cell body and shorter and thick processes 
whereas, in the neuroinflammatory situation, ramified microglia are activated characterized by 
swollen cell body and shorter, thick processes,  often exhibit rod-shape or amoeboid-like 
morphologies (Davis, Foster, and Thomas 1994).  
 
1.3. The role of astrocytes in neuroinflammation 
 
Astrocytes have an important role in brain homeostasis and it clear the metabolic waste from the 
brain (Iliff et al. 2012). It modulates the neuronal activity, potassium buffering and maintains the 
endothelial tight junctions (Parpura et al. 1994; Ballabh, Braun, and Nedergaard 2004; Iliff et al. 
2012). Astrocytes provide structural and functional support neurons. They are activated 
(reactive) in response to different pathological assaults to CNS, such as injury, trauma, growth of 
a tumor, or neuroinflammation which is termed as “reactive gliosis” (Fig 1) (Pekny and Nilsson 
2005). Previous few studies have quantified the number of astrocytes in adult murine CNS but 
these were based on assumptions to estimate the number per unit area. These studies have 
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reported an increase in astrocyte density in aged mice (Bronson, Lipman, and Harrison 1993; 
Mandybur, Ormsby, and Zemlan 1989; Sturrock 1980). One of the studies performed in the 
epilepsy model reported that aged rats present an increase in the expression of GFAP+ astrocytes 
26 days after neurodegeneration induced by intracerebroventricular kainite (KA) administration 
(Abdel-Rahman, Rao, and Shetty 2004). 
The morphology of astrocytes is considered to be an important factor for their functions 
(Gulbransen and Sharkey 2012). Astrocytes are classified based on morphology such as soma 
size, the number, and thickness of processes, length of processes into type I, II and III. Type I 
astrocytes have small soma and short processes, type II astrocytes have a bipolar shape and long 
processes. Type III astrocytes are star shape with long processes (Gulbransen and Sharkey 2012; 
Şovrea and Boşca 2013). Astrocytes are activated in response to many neuropathological 
situations which is characterized by high expression of GFAP protein, and an increase in number 
and length of GFAP+ processes. These findings have been interpreted as cellular hypertrophy 
(Kimelberg and Norenberg 1989).  
 
 
 
Figure 1. Entorhinal cortex lesion triggers reactive gliosis in the hippocampus. Unilateral entorhinal 
cortex lesion triggers astrocyte activation in the outer and middle molecular layer of the ipsilateral dentate 
gyrus of the hippocampus (Wilhelmsson et al. 2006) 
 
A study conducted in Friend Virus B NIH Jackson (Fvb/n) mice, in which the mice were 
exposed to contextual fear condition, and checked for morphological changes in astrocytes. One 
hour after fear conditioning, astrocytes exhibited cellular hypertrophy with an increased number 
and length of processes which differed from the typical resting or reactive state (Choi et al. 
2016). One of the studies performed on the human brain to compare morphometric analyses of 
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protoplasmic and fibrous astrocytes in Golgi-stained postmortem anterior cingulate cortex (ACC) 
samples from depressed suicides and non-psychiatric controls. The study found some significant 
differences between depressed and control groups such as a number of astrocytes processes, 
nodes, and spines that could reflect a state of chronic inflammation affecting the white matter in 
depression and suicide (Torres-Platas et al. 2011). 
 
1.4. Acute and chronic neuroinflammatory models in rodents  
 
Neuroinflammation is considered as an important component in the development of 
neurodegenerative diseases due to its presence in all neurodegenerative diseases along with 
reactive glial cells (Glass et al. 2010). To further investigate the role of neuroinflammation in 
neurodegenerative diseases, a number of rodent models have been used for the induction of 
chronic neuroinflammation. It includes toxin-induced models such as lipopolysaccharide (LPS)-
induced neuroinflammatory model, neurotoxin-induced models including colchicine-induced 
neuroinflammation, okadaic acid-induced neuroinflammation, and Streptozotocin-induced 
neuroinflammation. Apart from these, genetically manipulated models or transgenic models such 
as anti-nerve growth factor (NGF) transgenic models, IL-1β and IL-6 overexpression models 
have been used (Nazem et al. 2015).  
 
1.4.1 Toxin-induced models  
 
A number of studies demonstrated that LPS activates microglia both in vitro and in vivo, which 
subsequently triggers the release of NOS and a series of pro-inflammatory cytokines such as 
interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, and interferons (IFNs) (Palsson-
McDermott and O'Neill 2004; Block, Zecca, and Hong 2007a). Studies have found that after 
systemic administration, LPS induced inflammation via the up-regulation of different pro-
inflammatory cytokines and this lead to the activation of the inflammatory process which 
includes phosphorylation of P38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal 
kinase (JNK). Another study reported that LPS has a direct impact on IL-6 release from glial 
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cells and its signalling pathway. Incubation of glial cells with LPS for 2 h increased JAK2 and 
STAT1 phosphorylation, which ultimately results in the release of IL-6 and subsequent 
neuroinflammation (Minogue, Barrett, and Lynch 2012). LPS injection induced a potent 
activation of inflammatory signaling pathways in astrocytes and microglia in the brain through 
Toll-like receptor 4 (TLR4) and nuclear factor kappa B (NF-қB) signaling pathways (Noble et al. 
2007). The activation of these pathways, in turn, results in the release of pro-inflammatory 
cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin-1beta (IL-1β) (Kielian 
2006). The production of these cytokines and ROS ultimately leads to neuronal loss in the 
hippocampus and the subsequent cognitive impairment (Henry et al. 2008). Recently, the GFAP-
IL6 mouse model (transgenic model) is being used to induce neuroinflammation (Campbell et al. 
1993b; Campbell, Hofer, and Pagenstecher 2010). In this model, the IL6 gene was inserted into 
the promoter region of the glial fibrillary acidic protein (GFAP) gene and as a result, IL6 was 
constantly expressed along with GFAP. 
Similarly, another reliable model used in rodents is neurotoxin-induced neuroinflammation. 
Among them, the streptozotocin-induced neuroinflammatory model is considered as the most 
effective one. Glucosamine-nitrourea compound streptozotocin (STZ) damages beta cells of the 
pancreas, which makes it an animal model of diabetes mellitus (Like and Rossini 1976). 
Surprisingly, the STZ-induced diabetes model display impaired neuronal plasticity and learning 
deficits in rodents (Stranahan et al. 2008). A study performed in rats demonstrated that a single 
Intracerebroventricula (ICV) injection of 1 or 3 mg/ml STZ in rats has been proved to induce 
neuroinflammation, neurodegeneration, and atrophy of the septum in rats (Kraska et al. 2012). 
Moreover, STZ also contributes to ROS production, DNA damage, and apoptosis (Takasu et al. 
1991; Murata et al. 1999).  
D-galactose is a substance naturally exists in the body in a small amount. D-galactose model is 
also considered as a senescent model for age-related neurodegenerative diseases and 
neuroinflammation. One of the studies conducted on rats has used a chronic D-galactose model. 
D-galactose administered to the rats at dose of 50–500 mg/kg for 4–8 weeks showed a significant 
increase in inflammatory mediators e.g. COX-2, NOS2, IL-1β, and TNFα in D-galactose treated 
rats compared to those of the controls (Ullah et al. 2015)(Zhang and An 2007), hence attributed 
neuroinflammation, oxidative stress, and neurodegeneration (Zhang and An 2007).  
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1.4.2. Transgenic mouse models of neuroinflammation 
 
A number of genetically modified animal models have been used to study acute and chronic 
neuroinflammatory responses as well as for AD research. These include the p25 transgenic 
model, the anti-nerve growth factor (NGF) transgenic model (AD11 model), the TGF-β-deficient 
model, the IL-1β overexpression model, and the GFAP-IL6 mouse model. Regarding the GFAP-
IL6 mouse model, Campbell et al generated transgenic mice in which IL6 was overexpressed 
under the control of glial fibrillary acidic gene (GFAP) promoter and demonstrated the direct 
pathogenic impact of IL6 on inflammation and neurodegeneration of the CNS (Campbell et al. 
1993b). In the GFAP-IL6 transgenic mice, an increase in the levels of IL-6 is observed in most 
brain areas including the cerebellum, striatum, hippocampus, hypothalamus, neocortex, and 
pons, which results in accelerated age-related structural changes observed in 3–6 months old 
mice, but not in the WT mice (Vallieres et al. 2002).  
Most of the neurodegenerative diseases like AD are associated with inflammation characterized 
by activated microglia and astrocytes, increased cytokines and ROS production (Munch et al. 
1998). Amyloid precursor protein (APP) transgenic mice that show dementia pathology do not 
show all features of AD. For example, these mice generally develop a much weaker 
neuroinflammatory phenotype and do not share the same features of pro-inflammation compared 
with human AD patients (Johnston, Boutin, and Allan 2011). Whereas, GFAP-IL6 mice 
represent clear and severe neurological abnormalities characterized by seizures, tremors, and 
ataxia. These transgenic mice also show a clear neuropathological sign that includes 
neuroinflammation, gliosis, angiogenesis, and neurodegeneration, more proximal to that of 
human neurodegenerative diseases like MCP and HIV-associated dementia (Campbell 1998) 
(Fig 2). 
IL6 was discovered as an inflammatory cytokine involved in B cell differentiation (Kishimoto 
2010). Later on, a landmark study revealed that IL6 is supposed to be involved in the 
pathogenesis of various pathologic states including infection, autoimmunity, neurodegeneration, 
neuroinflammation, and trauma (Spooren et al. 2011). Based on the fact that IL6 is involved in 
the physiologic and pathophysiologic processes of the central nervous system, GFAP-IL6 
transgenic mice were generated to explore the neuropathological impact of IL6 overexpression. 
In this model, the mouse shows localized neuroinflammatory reaction and this might be 
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associated with a variety of neurological deficits manifested by various neurological disorders 
(Campbell, Hofer, and Pagenstecher 2010). Therefore, the GFAP-IL-6 animal model is a suitable 
animal model for studying neuroinflammation related neurodegenerative disorders (Campbell 
1998).  
 
 
Figure 2. Activation of microglia (Iba-1) increased in the cerebellum of GFAP-IL-6 mice with the passage of 
age (Gyengesi et al. 2019). 
 
1.4.3. Interleukin-6 (IL-6) 
 
IL-6 is a four-helical protein consisting of 184 amino acids. In the early 1980s, IL-6 was 
discovered as an inflammatory factor involved in B cell differentiation (Spooren et al. 2011). For 
more than two decades, IL-6 has been known to have a prominent role in stimulating the final 
maturation of B cells to antibody-producing cells (Hirano et al. 1986). Researchers claimed that 
IL-6 is involved in the pathogenesis of various pathologic states including infection, 
autoimmunity, trauma, acute phase response, liver regeneration, metabolic processes, gliogenesis 
and neurodegeneration (Spooren et al. 2011). Similarly, IL-6 expression is impaired in different 
diseases like atherosclerosis, asthma, rheumatoid arthritis, diabetes mellitus, cancers, and in 
different neurological and neuroinflammatory disorders (Hirano et al. 1990). In brain 
inflammation, there is activation of brain immune cells like microglia and astrocytes. In response 
to neuroinflammation, cytokines, chemokines, prostaglandins and reactive oxygen species (ROS) 
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are produced, which eventually leads to a number of neurodegenerative diseases such as AD and 
epilepsy (Wyss-Coray 2006). 
The source of IL-6 production is very diverse but astrocytes are considered to be the main CNS 
producers of IL-6. Neurotransmitters (e.g. norepinephrine), neuropeptides (e.g. vasoactive 
intestinal peptide, substance P), inflammatory cytokines (e.g. TNF-α, IL-1β), microbial 
pathogens (e.g. LPS), and IL-6 itself are the stimuli that trigger the production of IL-6 (Van 
Wagoner and Benveniste 1999; Gruol and Nelson 1997; Munoz-Fernandez and Fresno 1998). A 
number of studies have reported that IL-6 in the CNS is produced by the neuron as well. 
Therefore, astrocytes are not the only source of IL-6 (Streit et al. 2000). 
The function of IL-6 is variable and multipolar. Researchers claimed that IL-6 exerts both 
beneficial and destructive effects on the brain. (Loddick, Turnbull, and Rothwell 1998) reported 
the beneficial role of IL-6 in neuronal survival, protection, and differentiation, similar to what 
has been shown before that IL-6 increased survival and differentiation of primary neurons (Hama 
et al. 1991; Satoh et al. 1988). It has been reported that the injection of IL-6 into the ischemic 
region significantly reduced brain damage. On the other hand, several neurologists have 
correlated IL-6 with neurological disorders (Loddick, Turnbull, and Rothwell 1998). To support 
the neurotoxic effect of IL-6, Campbell et al, generated transgenic mice in which the IL-6 was 
overexpressed under the control of the promotor of glial fibrillary acidic protein (GFAP) gene 
(Campbell et al. 1993b). The GFAP-IL-6 transgenic mice have a high level of IL-6 protein 
expression characterized by a number of neurological diseases such as neurodegeneration, ataxia, 
seizure, tremor, and neuroinflammation. Furthermore, performed the immunolabeling of the 
brain sections with Anti-alpha 1 Antichymotrypsin (anti-ACT), showed an increase expression in 
the hippocampus and cerebellar white matter of GFAP-IL-6 mice compared to the control mice. 
As ACT production shoots up in AD and other neurological disorders, this study confirmed the 
claim that overexpression of IL-6 is a prominent cause of neurological diseases (Campbell et al. 
1993b). 
Cytokines have their own effect on the blood-brain barrier (BBB). IL-6 plays a prominent role in 
the maintenance of the blood-brain barrier integrity. In normal conditions, IL-6 acts as an anti-
inflammatory cytokine, helping to maintain blood-brain barrier integrity. In neuroinflammatory 
conditions, IL-6 block TNF-α-induced vascular cell adhesion molecule-1 (VCAM-1) 
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upregulation and inhibits TNF-α-induced intracellular adhesion molecule-1 (ICAM-1) 
expression in primary astrocytes, and ultimately, prevents the detrimental effect of TNF-α 
(Shrikant et al. 1995). Another study claimed that the increased level of IL-6 in the brain led to a 
proliferation of astrocytes and endothelial cells, which ultimately resulted in BBB breakdown 
(Campbell et al. 1994). Brett et al described that BBB never developed in IL-6 transgenic mice 
while in normal mice the BBB develops between 7 and 14 days. They studied two types of 
transgenic animals and found that the BBB was partially permeable until one month after birth in 
the low IL6 expression mice and complete absence of BBB was observed in the high IL6 
expression animals and they only survived for 6 months (Brett et al. 1995). It was also reported 
that axonal degeneration, macrophage accumulation, astrocytic foot process vacuolation, and 
gliosis widely spread in low and high expression IL-6 mice at the age of 6 and 12 months, 
respectively, compared to the control mice. These results clearly suggest the role of astrocytes 
and the effect of IL-6 overproduction on BBB breakdown and other neurophysiological functions 
(Brett et al. 1995). 
 
1.4.4. IL-6 signaling pathway and its pathogenic action in the brain 
 
IL-6 acts via interleukin receptors (membrane-bound IL-6Rα or soluble (s) IL-6Rα). The 
existence of interleukin receptors was discovered for the first time in urine (Novick et al. 1989) 
and later in the plasma (Honda et al. 1992). IL-6 belongs to a cytokine family in which almost all 
the cytokines have a common signal transducer, namely gp130 (glycoprotein 130/ CD130). Due 
to the presence of two types of IL-6 receptors, IL-6 mediates two types of cellular mechanisms: 
classic and trans-signaling pathways. In the classic signaling pathway, IL-6 binds to a specific 
transmembrane receptor termed IL-6Rα and forms a complex with gp130 protein, which induces 
homodimerization of gp130 (Campbell et al. 2014). The soluble form of the IL-6Rα (sIL-6R) is 
generated by cleavage of the ectodomain of the transmembrane IL-6Rα (Lust et al. 1992). In 
both types of pathways, dimerization leads to activation of the associated Janus kinases (JAK-1 
and JAK-2), which phosphorylates specific conserved tyrosine residues in the cytoplasmic 
domains of gp130. The phosphorylation of tyrosine residues leads to activation and translocation 
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of STATs to the nucleus where they modulate gene transcription. Therefore, this is also termed 
the JAK/STAT signaling pathway (Fig. 3) (Heinrich et al. 2003).  
 
 
Figure 3. IL-6 Signalling mechanisms: IL-6 binds to either non-transducing IL-6R or sIL-6R, which causes 
homodimerization of the transducer protein gp130. This leads to activate the association of JAKs and 
phosphorylation designated tyrosine residues in the cytoplasmic domains of gp130. After phosphorylation, STATs 
form homodimers, translocate to the nucleus and finally switch on the gene transcription. [Adopted from (Spooren et 
al. 2011) (Ullah et al. 2017)]. 
Studies have classified trans-signaling as pro-inflammatory and classic signaling as an anti-
inflammatory pathway on the bases of their action (Campbell et al. 2014). A study performed on 
14 
 
the trans-signaling mechanism of IL-6 and claimed that the pro-inflammatory activity of IL-
6/sIL-6R is blocked by a naturally occurring, soluble form of gp130 (sgp130). By generating 
single GFAP-IL6 transgenic mice and bigenic GFAP-IL-6/sgp130 transgenic mice, they found 
that blockade of trans-signaling by sgp130 protein significantly attenuates Serpina3n gene 
expression, angiogenesis, and blood-brain barrier leakage. In GFAP-IL6/ sgp130 mice 
degenerative changes in the cerebellum, blood vessels, and hippocampal neurogenesis were 
significantly decreased compared to those of GFAP-IL6 mice. As their previous study reported 
that neurodegeneration developed in the cerebellum of the GFAP-IL6 mice (Campbell et al. 
1993) and the signaling pathway of IL-6 was mediated through the activation of STAT-3 
phosphorylation. In bigenic mice, sgp130 was able to block IL-6 trans-signaling and hence, pY-
STAT3 activation was reduced 2.5 folds in the GFAP-IL6/sgp130 bigenic mice compared to 
GFAP-IL6 mice (Campbell et al. 2014). 
 
1.4.5. IL-6 signalling and microglial activation. 
  
Interleukin-6 (IL-6) was originally identified as a B-cell differentiation factor (BSF-2) that 
induced the maturation of B cells into antibody-producing cells (Hirano et al. 1985). It is a 
unique cytokine that can act as both pro- and anti-inflammatory depending on the anatomical site 
and conditions under which it gets activated (Bobbo et al. 2019). There is very limited 
information about the direct role of IL-6 in the regulation of microglia in the literature.  Stress 
situations or any kind of foreign insult lead to the activation of microglia which release 
cytokines, including IL-6, in addition to other chemokines and growth factors, in order to 
mitigate or prevent damage to the brain due to the insult. The relationship between microglia and 
IL-6 in the brain remains very unclear. The activation of IL6 in the brain occur due to different 
kinds of stimulus such as LPS, diet, trauma or neuroinflammation  which leads to actiation of 
many signalling pathways (Mendes et al. 2018). LPS from the diet are recognized by TLR4 in 
microglial cells, increasing the production and release of several inflammatory cytokines 
including IL-6 (Milanski et al. 2009) whereas, neonatal overfeeding beginning early in life 
increases the TLR4 expression in the hypothalamus and the number of Iba-1 (microglia) positive 
cells, followed by increased expression of IL-6 (Ziko et al. 2014). Emerging shreds of evidence 
suggest that microglial IL-6 production is more strongly associated with the activation of P2Y 
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receptors (Shigemoto-Mogami et al. 2001). Several studies have reported that curcumin is able to 
inhibit the IL-6 signalling by inhibiting the phosphorylation and nuclear localization of STAT3, a 
well-known downstream mediator of IL-6 signalling (Devi et al. 2015) 
 
1.5. Cytokine suppressive anti-inflammatory drugs (CSAIDs) as a potential therapeutic 
agent, molecular signalling and curcumin concentrations in the brain. 
 
The pharmacotherapy of inflammatory conditions is based mainly on the use of non-steroidal 
anti-inflammatory drugs (NSAIDs). However, NSAIDs have limited anti-inflammatory action, as 
they are specific inhibitors of cyclooxygenases (COXs). Epidemiological studies suggest that 
current or former NSAID is significantly associated with reduced risk of AD compared with 
those who did not use NSAIDs. However, the ADAPT study results revealed that treatment for 1 
– 3 years with naproxen or celecoxib did not protect against cognitive decline in older adults 
with a family history of AD (Breitner et al. 2011). 
NSAIDs do not influence the production of pro-inflammatory cytokines such as IL1, IL6, TNF-α 
or nitric oxide produced by iNOS (Gunawardena et al. 2015). Therefore, drugs with a broader 
range of anti-inflammatory effects than NSAIDs may be more effective for the prevention and 
treatment of AD. One promising drug class in this respect might be cytokine suppressive anti-
inflammatory drugs (CSAIDs) which target the pro-inflammatory AP1 and NF-κB signaling 
pathways and inhibit the expression of many pro-inflammatory cytokines in the low µM range 
(Zhang, Li, et al. 2013).   
One of the most interesting CSAIDs is the main ingredient of the spice turmeric (Curcuma 
longa), curcumin. Curcumin has a broad cytokine-suppressive anti-inflammatory action, down-
regulating the expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), 
TNF-α, IL-1, -2, -6, -8, and -12. It inhibits IL-6 mediated signaling via inhibition of IL-6 induced 
STAT3 phosphorylation and consequent STAT3 nuclear translocation (Bharti, Donato, and 
Aggarwal 2003), and interferes with the first signaling steps downstream of the IL-6 receptor 
(“the inflammatory trigger”) in microglial activation (Ray and Lahiri 2009).  
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Numerous studies have reported that curcumin suppresses IL-6-
induced STAT3 phosphorylation and IFN-alpha-induced STAT1 phosphorylation and promotes 
survival. A study performed in human multiple myeloma (MM) cells has reported that 
curcumin inhibited IL-6-induced STAT3 phosphorylation and consequent STAT3 nuclear 
translocation (Bharti, Donato, and Aggarwal 2003). Another study investigated the effect of 
curcumin on IL-6 induced expression in HuF cells, primary human fibroblast cells, and UIII 
cells, a rodent non-transformed decidual cell line. The study reported that curcumin inhibited the 
expression of gp130, a critical molecule in IL-6 signalling and inhibited phosphorylation and 
nuclear localization of STAT3, a well-known downstream mediator of IL-6 signalling (Devi et 
al. 2015). Curcumin targets numerous signalling pathways associated with neuroinflammation 
and related disorders. One of the studies reported that curcumin significantly reduced spatial 
memory deficit and promoted the function of cholinergic neurons in mice by the inhibition of 
NF-kappaB signalling pathways and enhanced transcription by PPAR-gamma (Liu et al. 2016). 
One study performed in the LPS mouse model has reported that curcumin inhibited the Toll-like 
receptor 4 (TLR4)-mediated downstream signalling and effectively lowered the production of 
inflammatory mediators (Youn et al. 2006). Curcumin has several potential receptors through 
which it gets into the cell. A study characterized the accumulation of curcumin in membrane 
structures of mammalian cancer cells (Ishikawa cells), derived from a human endometrial 
carcinoma, and HT-29 cells, derived from human colon adenocarcinoma. The results indicated 
that curcumin rapidly penetrates the plasma membrane of mammalian cells and binds to the 
membranes of the endoplasmic reticulum (Dempe, Pfeiffer, and Metzler 2007). Despite its 
various pharmacological and therapeutic activities, the instability  of curcumin at physiological 
pH and its susceptibility to intestinal and hepatic metabolism have limited its therapeutic use. 
Although curcumin is well absorbed in glucuronidated and sulfated forms by the intestine and 
liver, which increases hydrophobicity, and therefore limits blood-brain barrier permeability and 
lowers bioavailability to the brain (Wang et al. 1997; Anand et al. 2007). However, free 
curcumin is membrane permeable because it is lipophilic and fulfills the Rule of 5 characteristics 
of blood-brain barrier permeable molecules. To decrease the glucuronidation of curcumin, the 
use of piperine has been recommended (Jager et al. 2014). To increase its stability and 
subsequent bioavailability, a number of different encapsulation approaches have been employed 
including the use of liposomal curcumin, including Longvida (LC) curcumin. 
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Several literature studies have reported that curcumin gets into the brain and can achieve a steady 
state concentration. One study conducted in the LPS mouse model has identified the 
concentration of curcumin in the mice brain and plasma. Curcumin was orally fed to mice 50 
mg/kg dose, once daily for 2 consecutive days and then i.p. injected with 5 mg/kg LPS or 
vehicle. Two hours after LPS injection the mice were culled and the brain concentration of 
curcumin was 41.1 ± 6.7 ng/g and plasma contained very low concentrations of curcumin (8.2 ± 
1.8 ng/g), with the sulphate and glucuronide metabolites being more abundant (67.0 ± 10.2 ng/ml 
and 453.2 ± 110.2 ng/ml, respectively) (Sorrenti et al. 2018). Another study performed in rats has 
localised the nanocurcumin formulation in the rat brain. Three different types of liposomal 
formulation were injected intravenously and one hour later, up to 0.5% of the injected material 
localized in the brain stem, the striatum, and the hippocampus with different  accumulation and 
clearance rates using HPLC sensitive assay  (Chiu et al. 2011). Pharmacokinetics of unmodified 
curcumin is unfavorable, and its bioavailability is low. However, highly bioavailable curcumin 
formulations (encapsulated in liposomes or micelles) such as LC (VS Corp) can achieve µM 
concentrations in the rodent brain (Begum et al. 2008a; Ma et al. 2013b). A study conducted in 
APPSw mice, have used a low (160 ppm) and a high dose of dietary curcumin (5000 ppm), 
which reported that the  low and high doses of curcumin significantly lowered oxidized proteins 
and interleukin-1, the astrocytic marker GFAP was reduced, plaque formation was significantly 
decreased by 43-50% (Lim et al. 2001).  
 
1.5.1. Origin and efficacy of curcumin  
 
Turmeric spices have been a source of drug and traditional medicines since ancient times. They 
have been used for at least 2,500 years, mostly in Asian countries. They have derived from the 
dry rhizomes of plant Curcuma longa which belongs to the Zingiberaceae family or ginger 
family (Mathew and Pushpanath 2005). Turmeric is widely produced in India as well as in 
Pakistan, Bangladesh, China, Indonesia and South America (Norman 1991). The most active 
component of turmeric is curcumin, which constitutes up to 2–5% of the spice. Besides 
curcumin, turmeric may contain essential oils, carbohydrates, polyphenols, proteins, fat, minerals 
and moisture (Chattopadhyay et al. 2004). Turmeric is an effective traditional medicine and has 
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been used as a remedy to treat various disorders including rheumatism, body aches, skin 
diseases, wounds, intestinal worms, diarrhea, hepatic disorders, biliousness, urinary discharges, 
dyspepsia, inflammation, constipation, leukoderma, amenorrhea, and colic inflammation 
(Aggarwal, Surh, and Shishodia 2007). In addition to its traditional medicinal use, it has been 
used by the food industry as a flouring and coloring agent in soft drinks and beverages as well as 
Ayurveda medicine in oxidative stress, pyrexia and as an anti-inflammatory agent (Aggarwal, 
Surh, and Shishodia 2007). 
Curcumin, a polyphenolic compound, has a yellow pigment and aromatic smell (Jayaprakasha, 
Jagan Mohan Rao, and Sakariah 2005). Recently, considerable attention has been drawn towards 
curcumin because of its numerous pharmacological applications including antioxidant, anti-
inflammatory, antiviral, antibacterial activities as well as the therapeutic potential for cancer, AD 
and other neurological disorders (Goel, Kunnumakkara, and Aggarwal 2008; Goel and Aggarwal 
2010). It has been reported that curcumin scavenges free radicals such as reactive oxygen species 
(ROS) and inhibits ROS-generating enzymes like xanthine dehydrogenase/oxidase and 
lipoxygenase/cyclooxygenase (Menon and Sudheer 2007). It was reported that curcumin has 
anti-carcinogenic, antibacterial, and anti-inflammatory activities (Anand et al. 2008). It inhibits 
TNF-α induced or IL-1-induced activation of NF-κB and decreases pro-inflammatory cytokines 
in cells (Singh and Aggarwal 1995).  
 
 
1.5.2. Structure and chemistry of curcumin and curcuminoids 
 
Curcumin is a bis-α, β-unsaturated β-diketone with a molecular weight of 368.38g/mol. Its 
chemical name is: (E, E)-1, 7-bis (4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5 dione) with 
a melting point of 179–183 °C.  In 1815, Vogel and Pelletier purified curcumin from turmeric for 
the first time while its structure as diferuloylmethane was not established until 1910 (Milobedzka 
J 1910). Its chemical structure was confirmed in 1973 by Roughley and Whiting (Roughley and 
Whiting 1973). Turmeric contains a group of compounds called curcuminoids which make up 
2% to 9% of turmeric. The group of curcuminoids includes three compounds named 
curcumin/diferuloylmethane, desmethoxycurcumin, and bisdemethoxycurcumin with a 
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proportion of approximately 77%, 18%, and 5% respectively (Fig. 4) (Basnet, Tho, and Skalko-
Basnet 2010).   
 
             Figure 4.  Chemical Structure of three different curcuminoids adapted from (Wilken et al. 2011) 
As far as the structure of curcumin is concerned, it belongs to the diaryl hepatanoid class of 
compounds. It has a seven carbon chain with two aromatic rings attached at both ends. The two 
phenolic rings are linked via an aliphatic unsaturated heptene linker in the para-position that also 
contains β diketonic functionality on carbon-3 and -5 (Priyadarsini 2013). Curcumin probably 
exists in equilibrium between keto and enol tautomer.  A number of studies have demonstrated 
that enolic- and ketonic-forms of curcumin interconvert in solution in a reversible manner 
(Payton, Sandusky, and Alworth 2007). Tautomerization of curcumin occurs under the influence 
of temperature, the polarity of the solvent, the substitution of the aromatic rings, and pH 
(Cornago et al. 2008). At pH 3-7, the curcumin molecules remain in bis-keto form and act as a 
potent proton donor but at pH > 8 the enolate form of the heptadienone chains predominates and 
it behaves as an electron donor (Wang et al. 1997). The enolate form of curcumin is found to 
have the radical scavenging ability which entitles curcumin to its antioxidant property (Sharma, 
Gescher, and Steward 2005). 
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1.5.3. Role of curcumin as an anti-inflammatory agent 
 
Experiments have demonstrated that curcumin treatment reverses the activation of microglial 
cells in the brain by inhibiting the production of NO in the brain and decreases the secretion of 
pro-inflammatory cytokines such as IL1β, IL6, and TNF-α (Jung et al. 2006; Jin et al. 2007). It is 
well known that lipopolysaccharide (LPS) is able to induce iNOS in microglial cells of CNS. 
Studies showed that curcumin counteracts the LPS- induced cyclooxygenase-2 (COX2) by 
targeting different signaling pathways like NF-қB inhibition pathway, activator protein 1 (AP1), 
signal transducers and activators of transcription (STATs) (Kang et al. 2004; Kim et al. 2003). 
Curcumin can attenuate IL6 induced neuroinflammation both in vitro and in vivo. Curcumin 
attenuates LPS induced neuroinflammation and cytokine production in BV2 microglia cell line 
(Cheng et al. 2001). In this study, BV2 microglia cells were incubated with curcumin (0, 5, 10, 
and 20 μM/L) in the presence or absence of LPS (0.5 μg/ mL). The level of cytokines (IL-1β, IL-
6, and TNF-α) in the culture media was measured using ELISA. Interestingly, pre-treatment with 
curcumin resulted in a dose-dependent decrease in cytokine production (Cheng et al. 2001). 
Another study performed in Dalton’s lymphoma (DL) mouse model also revealed the protective 
effect of curcumin against IL6 induced inflammation. They reported that the level of IL-6 in DL 
and DL+DMSO mice was up-regulated to double that of normal mice, treatment with curcumin 
significantly reduced the level of IL-6 to 65%, 53% and 71% of that of DL+DMSO mice with 
doses of 50, 100 and 150 mg/kg bw, respectively (Das and Vinayak 2014). The protective effect 
of curcumin against inflammatory cytokines has been reported by many researchers. A recent 
study reported that curcumin pre-treatment reverses or stops the secretion of TNF-α and IL6 by 
MPP+ treated astrocytes (Yu et al. 2016). Another study reported the effect of curcumin on LPS-
stimulated microglia (BV2) cell line and the regulation of pro-inflammatory cytokines (IL-1β, 
IL-6, and TNF-α). Curcumin had no effect on the production of IL-1β, IL-6, and TNF-α in 
normal BV2 microglia, but decreased the cytokine production level in a dose-dependent manner 
in LPS-treated microglia (Jin et al. 2007). 
In a study, curcumin was studied in a traumatic brain injury (TBI) model. Many activated TLR4-
positive microglia/macrophages were observed post-trauma and various inflammatory mediators 
like interleukins and cytokines were found in the injured brain of TBI groups compared to the 
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control. Curcumin, administered at 100 mg/kg, significantly reduced the expression of cytokines 
and the number of activated microglia compared to the untreated group (Zhu et al. 2014). Similar 
results were observed in other animal models of neurological disorders like depression. Olfactory 
bulbectomy (OBX) is used to create a depression model by inducing changes in behavioral and 
biochemical actions in experimental subjects (Song and Leonard 2005). Levels of TNF-α and 
caspase 3 were raised in olfactory bulbectomized (OBX) rats compared to controls. Treatment 
with curcumin (100, 200 mg/kg) and piperine (20 mg/kg) significantly reduced the level of TNF-
α and caspase 3 and this effect was much more effective than using curcumin or piperine alone 
(Rinwa, Kumar, and Garg 2013).  
For neuroinflammation therapeutics, curcumin is a compound of choice compared to the α-
tocopherol (vitamin E), a poor scavenger for NO-related oxidative and to nonsteroidal anti-
inflammatory drugs (NSAIDs) that have adverse effects including gastric ulcer, liver, and kidney 
toxicity (Chan et al. 1998; Hanai et al. 2006). A couple of studies demonstrated that curcumin 
administration reverses neuroinflammation and attenuates cognitive impairment in AD models 
(Yang et al. 2005; Garcia-Alloza et al. 2007). Moreover, curcumin fed orally has been reported 
to be effective in animal models for conditions like oxidative stress, cancer, diabetes, 
atherosclerosis, arthritis, stroke, peripheral neuropathy, inflammatory bowel disease (Aggarwal, 
Surh, and Shishodia 2007). 
Studies have shown that astrocytes and microglia play a pro-inflammatory role through toll-like 
receptor (TLRs) and the subsequent production of various inflammatory mediators including 
cytokines, chemokines, and reactive oxygen species (Farina, Aloisi, and Meinl 2007; Hirsch and 
Hunot 2009). Toll-like receptors (TLRs), a group of receptors (TLR2, TLR3, TLR4, and TLR9) 
present in immune cells like astrocytes and microglia (Bowman et al. 2003), are activated by 
exogenous stimuli or pathogens, leading to the activation of the intracellular signal pathways 
(Akira, Takeda, and Kaisho 2001; Zhang, Tang, et al. 2013). A recent study on curcumin 
reported that it decreases the level of pro-inflammatory cytokines and ROS in the brain, 
confirming the pro-inflammatory role of curcumin (Aggarwal, Gupta, and Sung 2013). 
One of the other studies reported that fructose in the diet induces fractalkine (FKN) and 
modulates the inflammatory status of microglia via CX3CR1 in animal models of obesity 
through Toll-like receptor 4 (TLR4)/nuclear transcription factor кB (NF-кB) signaling pathway. 
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Curcumin treatment reverses the neuronal damage, microglial activation, neuroinflammation and 
downregulated FKN/CX3CR1 up-regulation in the neural network by decreasing the level of IL-
1β, TNF-α, IL-6, and Iba1- a microglial marker in both hippocampus and hypothalamus of 
fructose-fed mice (Cardona et al. 2006). 
1.5.4. Available curcumin formulations 
 
Despite its multi neuroprotective properties, curcumin’s use is limited due to its low brain 
bioavailability which attributes to its poor absorption, rapid metabolism, rapid systemic 
elimination, and limited blood-brain barrier (BBB) permeability (Tsai et al. 2011). The most 
challenging factor is its low water solubility (0.4µg/ml at normal pH). The solubility of curcumin 
is very sensitive to physiological pH (Tonnesen 1989, 2002). Preclinical studies on rodents and 
clinical studies on humans have reported low bioavailability of curcumin shown by the lower 
level of serum curcumin (50ng/ml) after feeding with 10-12 g/ml of orally administered 
curcumin (Vergoni et al. 2009). Many approaches have been applied to enhance the 
bioavailability of curcumin such as using the structural analogs of curcumin, the use of adjuvants 
like piperine and phospholipids. To cope with these limiting factors and to improve its 
bioavailability in the brain, biodegradable nanoparticle-mediated delivery of curcumin may be 
the best approach to increase its intracellular transport and prevent degradation (Tsai et al. 2011). 
A couple of recent studies suggest that delivery of an encapsulated compound of low aqueous 
solubility, poor absorption, rapid metabolism, and low BBB permeability is more effective than 
delivering parent compound, which yields a higher BBB permeability (Vergoni et al. 2009; 
Hoppe et al. 2013).  
Several studies have compared raw curcumin and various curcumin formulations and reported 
the bioavailability of the curcumin formulations. A human study was conducted to quantify the 
plasma levels of free curcumin after dosing of a solid lipid curcumin particle (SLCP) formulation 
versus unformulated curcumin in healthy volunteers and osteosarcoma patients. Doses of 2, 3, 
and 4 g of SLCP were evaluated. Using a high-performance liquid chromatography method, the 
mean peak concentration of curcumin achieved from dosing 650 mg of SLCP was 22.43 ng/mL, 
whereas plasma curcumin from dosing an equal quantity of unformulated 95% curcuminoids 
extract was not detected (Gota et al. 2010). The molecular modification of MCP was designed 
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for human consumption and was proved to be more effective in humans in other studies, such as 
lecithin formulation (Meriva) and standardized curcuminoid mixture was investigated in a 
randomized, double-blind, crossover human study. The study investigated that the total 
curcuminoid absorption was about 29-fold higher for Meriva than for its corresponding 
unformulated curcuminoid mixture. This better plasma curcuminoid profile might underlie the 
clinical efficacy of Meriva at doses significantly lower than unformulated curcuminoid mixtures 
(Cuomo et al. 2011). 
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Table. 1 Available curcumin formulations  
 
 
 
Curcumin 
formulation  
Company 
Name and 
Address 
Type of 
Formulati
on/Dosage 
form 
Composition Dosage Reference Study 
Huma
n/Ani
mals 
Cmax   Comments 
1 Meriva® Indena 
S.p.A. 
Italy 
Phytosome Curcumin (20%), 
hydroxypropyl 
methylcellulose and 
Calcium Citrate 
Laurate,  
Hypromellose 
(derived from 
cellulose) capsule, 
Leucine, Silicon 
Dioxide, 
Microcrystalline 
Cellulose & 
phytosome 
 
MCP  high 
& MCP 
low{200-
300mg} 
Cuomo et 
al.,2010 
Human 538.0±130.7ng/ml 
272.6± 68.52ng/ml 
A randomized, double-blind, crossover 
study was carried out 
in nine volunteers by five (low-dose) or 
nine (high-dose) capsules of MCP 
2 Longvida® Verdure 
Sciences, 
USA. 
Liposome Curcumin (20%), 
Plant derived 
cellulose, soy 
lecithin, stearic acid 
(from vegetable), 
dextrin, ascorbyl 
palmitate (vitamin c), 
80 mg/day 
for 4 
weeks 
DiSilvestro 
et al.,2012 
Human N.R The study was conducted in healthy 
middle aged people (40–60 years old). 
Subjects were given either curcumin 
(N = 19) or placebo (N = 19) 
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silicon dioxide and  
microcrystalline 
cellulose  
3 Curcumin 
C3 
complex® 
Sabinsa 
Corporatio
n, 
Australia  
Curcumino
ids with 
BioPerine
® 
Curcuminoids 
(including: 
Bisdemethoxycurcum
in – 2.2% to 6.5% 
Demethoxycurcumin 
– 15% to 19% 
Curcumin – 75% to 
81%)      
BioPerine®† Black 
Pepper Standardized 
Extract (Piper nigrum 
) 
Dose = 10 
g (n = 6) 
Dose = 12 
g (n = 6) 
Shaiju K et 
al.,2008 
Human 3.2±0.56 µg/ml 
2.1±0.73 µg/ml 
Twelve healthy human subjects 18 y of 
age or older, with normal organ function 
were recruited.Subjects included five 
males and seven females  
4 Sabinsa C3 
complex® 
Dose = 10 
g          
Dose = 12 
g  
Vareed et 
al.,2014 
2.3±0.56 µg/ml 
1.7±0.73 µg/ml 
 
This study was conducted in healthy 
human volunteers for 0.25-72 hours after 
a single oral dose. 
5 Theracurmin
® 
Curcumin
Rich™, 
USA 
Capsules 
containing 
colloidal 
particles 
Curcumin (10%) 
from turmeric 
(Curcuma longa) 
(rhizome) 
150 mg 
and after 
an interval 
of two 
weeks 210 
mg 
Kanai et 
al.,2012 
Human 150 mg = 189 ± 48  
& 210 mg =275 ± 
67 
Six healthy human volunteers were 
recruited and received THERACURMIN 
at a single oral dose of 150 mg and after 
an interval of two weeks, the same 
subjects then received THERACURMIN 
at a single dose of 210 mg 
6 Biocurcuma
x™BCM95
® 
DolCas 
Biotech 
,USA 
Capsules Combination of 
curcuminoids (86%) 
plus essential oils (7-
9%) 
 
4×500 mg 
capsules 
Antony et 
al., 2008 
Human 456.88 ng/g 11 individuals, the study was performed 
in India, no information on diet except to 
avoid foods containing turmeric two days 
prior to the study date 
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7 NovaSOL® 
Curcumin 
AQUANO
VA AG 
(Darmstadt
, Germany 
Curcumin 
micelles 
(Capsules) 
Curcumin, 
Polysorbate, Ascorbic 
Acid, Medium Chain 
Triglycerides 
500mg  
 
Schiborr et 
al., 2014 
Human 3228±1408.2 
nmol/l 
Total 23 healthy subjects (13 women, 10 
men) took,  
a single oral dose of 500 mg 
curcuminoids, micronized powder, 
or liquid micelles randomly. Blood and 
urine samples were collected for 24 h 
 
8 
 
 
Pure 
curcumin 
powder 
Provided 
by the 
National 
Cancer 
Institute’s 
Division of 
Cancer 
Prevention 
Capsules Curcumin powder  2 g (8 
capsules) 
once daily 
4 g(16 
capsules) 
once daily  
Carroll et 
al., 2011 
Human Pre-intervention 
7.3±8.1 ng/ml 
 
Post-intervention 
3.8±1.3 
A phase IIa cancer prevention trial of oral 
curcumin given daily for 30 days in two 
stages on 40 participants. 
9 Curcumin 
phytosome 
(CP), 
 
Indena 
USA Inc., 
Seattle, 
WA, USA 
 
 
 
 
 
 
Gel 
capsules 
Curcumin plus 
phosphatidylcholine 
(PC) 
376 mg Jäger et al., 
2014 
Human 2.8 ± 0.3ng/ml 
 
Fifteen subjects (11 males, 1 female) 
were recruited for this study. One subject 
never started the study and the other two 
drop-outs. Each volunteer passed through 
screening and completed 4 trials in 7 
days. 
Curcumin 
turmeric 
rhizome 
(CTR) 
DolCas 
Biotech, 
LLC, 
Landing, 
NJ, USA 
 
Curcumin 
formulation with 
volatile oils 
376 mg 0.5 ± 0.0ng/ml 
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Curcumin 
with 
hydrophilic 
carrier, 
(CHC) 
 Health 
Technologi
es, Inc., 
Morristow
n, NJ, 
USA 
 
Curcumin with a 
combination of 
hydrophilic carrier, 
cellulosic derivatives 
and natural 
antioxidants 
376 mg 27.3 ± 6.4# ng/ml 
 
 
Standardized 
curcumin 
mixture (CS) 
Sabinsa 
Corporatio
n, East 
Windsor, 
NJ, USA 
Standard curcumin 1,800 mg 2.3 ± 0.3ng/ml 
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1.5.4.1. Curcumin Phytosome, Meriva by Indena 
 
Phytosome technology emerged in the late 80s (Bombardelli et al. 1989). The term phytosome 
refers to the molecular-level association of the polyphenol chemically bound with a phospholipid 
preparation, consisting mainly of phosphatidylcholine (PC). Researchers have found from 
systematic bioavailability comparison that oral administration of phytosome enhances and 
strengthens the blood level of polyphenol constituents by at least 2-6 times (Indena SA). Most of 
the polyphenol molecules have a large chemical structure and cannot be absorbed by simple 
processes of diffusion due to their poor solubility in the water or lipids (Manach et al. 2004). On 
the other hand, PC is an amphipathic molecule with a unique structure having a positively 
charged head group and two neutrally charged tail groups that proffer it miscible in both water 
and lipid (Kidd and Head 2005). MCP® is a patented curcumin formulation from Indena S.p.A. 
Milan, Italy. It is formulated in a 1:2 weight ratio of curcumin and soy lecithin with an overall 
20% of curcumin content in the final product. Some preliminary data on MCP curcumin have 
been collected so far and clinical trials have been conducted on MCP curcumin against 
osteoarthritis, diabetic mellitus, and microangiopathy. 
MCP is the embedded dosage from Indena, designed to improve the bioavailability of 
compounds like polyphenolics and triterpenoid acids, that are normally characterized by poor 
water solubility and low solubility in organic solvents as well (Kidd 2009). Meriva® is a 
Curcumin phytosome, a patented complex with phosphatidylcholine (Semalty et al. 2010). There 
are two factors which mainly influence the bioavailability of natural products: hydrophilicity and 
lipophilicity. Most of the polyphenolics like curcumin have good water solubility but are poorly 
absorbed because of their poor miscibility with oils and their large particle size (Manach et al. 
2004). In order to counteract the low bioavailability of these phytoconstituents, polyphenolics are 
modified into a lipid-compatible molecular complex known as Phytosome®. The phytosome® is 
made up of Phospholipids (small lipid molecules) mainly phosphatidylcholine, and a lipophilic 
substance which is more bioavailable than phytoextract due to its high capacity to cross the lipid-
rich biomembranes and reach the circulation (Bombardelli et al. 1989; Citernesi and 
Sciacchitano 1995; Mauri et al. 2001). It is amphiphilic in nature having the property of 
improving solubility and bioavailability of both high lipids insoluble and poorly water-soluble 
phytoconstituents. Moreover, it improves systemic bioavailability of the attached substances 
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when administered orally (Barzaghi et al. 1990; Morazzoni et al. 1992; Maiti K 2005). There are 
a number of available Pytosome® complexes in the market owned by Indena S.p.A. Milan, Italy 
such as Crataegus Phytosome® (Antioxidant), Escin ß-sitosterol Phytosome (Anti-oedema), 
Silymarin Phytosome® (Antihepatotoxic) and MCP ™ (Anti-inflammatory) (Semalty et al. 
2010). 
By complexing a polyphenol like curcumin with PC to make phytosome, the embedded 
curcumin adopts some of the PC’s versatile solubility properties. Moreover, PC molecules 
enhance the dispersion and bioavailability of the poorly water-soluble curcumin molecules. In 
order to evaluate the hypothesis that curcumin phytosome with soy phosphatidylcholine MCP 
might improve the systemic availability of curcumin. Various studies have been performed to 
compare the effect of MCP with curcumin to figure out its efficacy and bioavailability. One of 
the comparative pharmacokinetic studies performed on male Wistar rats has confirmed the high 
bioavailability of biocompatible curcumin. They feed to male Wistar rats orally raw curcumin 
and MCP at the dosage of 340 mg/kg and 1.8 g/kg respectively. After 15, 30, 60 and 120 minutes 
of administration, the presence of curcumin and other metabolites in the plasma, liver and 
intestinal mucosa was analyzed. It turned out that 99% of curcumin was present in plasma as 
glucuronides, with the remaining 1% being curcumin sulphate and free curcumin whereas 
curcumin formulation with phospholipids (MCP) increased the plasma concentration of 
curcumin up to 20-fold (Marczylo et al. 2007).   
It has been shown that the phytosome® complexes have a better anti-inflammatory effect than 
uncompleted herbal extracts (Bombardelli et al. 1989; Bombardelli, Cristoni, and Morazzoni 
1994). Several clinical trials are going in support of MCP curcumin. The absorption and ultimate 
bioavailability were examined in human subjects for both curcuminoid and MCP at the same 
time. The absorption of the unformulated curcuminoid mixture was 29-fold less as compared to 
MCP (Cuomo et al. 2011). Another study investigated the activity of curcumin in neurogenesis 
in AD brain. It was found that curcumin-encapsulated PLGA nanoparticles (Cur-PLGA-NPs 
potently induce NSC proliferation and neuronal differentiation in vitro and in the hippocampus 
and subventricular zone of adult rats as compared to uncoated bulk curcumin (Tiwari et al. 
2014). 
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Taken together all these studies, it is concluded that the curcumin efficacy and potency can be 
enhanced by delivering it in a controlled and embedded manner to a target site and phytosome is 
expected to be the better candidate for delivery for curcumin particles. 
 
 
Figure 5. Meriva curcumin. The MCP in raw form (http://www.indena.com/)  
1.5.4.2. Solid lipid curcumin particle (SLCP), Longvida by Verdure Sciences 
 
The SLCP preparation (Longvida, SLCP), consist of dispersible solid lipid curcumin particles, 
and a curcumin extract (containing 95% curcuminoids) patented by Verdure Sciences 
(Noblesville, IN, USA). Briefly, dry turmeric root extract powder was mixed with 
phosphatidylcholine, vegetable stearic acid, ascorbic acid (vitamin C) Palmitate, and other inert 
ingredients manufactured under cGMP standards for precise chemical and physical 
characteristics. This patented Solid Lipid Curcumin Particle (SLCP) Technology enables the 
uptake of free curcumin to the blood and target tissues. 
Curcumin has a broad cytokine-suppressive anti-inflammatory action, down-regulating the 
expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), TNF-α, IL-1, -
2, -6, -8, and -12. It inhibits IL-6 mediated signalling via inhibition of IL-6 induced STAT3 
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phosphorylation and consequent STAT3 nuclear translocation (Bharti, Donato, and Aggarwal 
2003), and interferes with the first signalling steps downstream of the IL-6 receptor (“the 
inflammatory trigger”) in microglial activation (Ray and Lahiri 2009). Pharmacokinetics of 
unmodified curcumin is unfavourable, and its bioavailability is low. However, highly 
bioavailable curcumin formulations (encapsulated in liposomes or micelles) such as Longvida 
curcumin (VS Corp) can achieve µM concentrations in the rodent brain (Begum et al. 2008a; Ma 
et al. 2013b). As mentioned earlier, due to the poor bioavailability and extensive phase-II 
metabolism of curcumin, the oral dosage form of curcumin formulations has very limited 
bioavailability and absorption, which limits its potential as a preventive and/or therapeutic agent 
(Anand et al. 2007). Several clinical studies have reported low systemic bioavailability of normal 
curcumin even after 12 g/day oral administration (Olivera et al. 2012).  
Studies have been conducted on LC with positive outcomes. A study conducted in aged human 
tau transgenic mice have reported that the LC selectively suppressed soluble Tau dimers and 
attenuated the synaptic and behavioral deficits in transgenic mice (Ma et al. 2013a). Moreover, 
acute and chronic animal studies and the No Observed-Adverse-Effect Level (NOAEL) were 
determined to be 720 mg/kg bw/day (Dadhaniya et al. 2011).  
Clinical studies conducted on LC have reported the increased bioavailability and absorption 
compared to free curcumin (Gota et al. 2010). A study demonstrated that a low dose of LC 
(80 mg/day) have shed health-promoting effects on aged-human (DiSilvestro et al. 2012). Highly 
bioavailable curcumin preparations, the LC has achieved higher concentrations in the brain and 
significantly improved working memory and mood after a 4 week treatment in a randomized, 
double-blind, placebo-controlled human trial (Begum et al. 2008b; Wu et al. 2014). From the 
previous studies, it could be assumed that the curcumin efficacy and potency can be enhanced by 
delivering it in a controlled and embedded manner to a target site and SLCP is expected to be the 
better candidate for delivery for curcumin particles. 
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Figure 6. Longvida curcumin (https://vs-corp.com/l) 
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2.  Hypothesis and Research aims 
 
2.1 Hypothesis  
 
In the GFAP-IL6 mouse model, chronic neuroinflammation starts early from the age of 3 
months, having a higher number of activated microglia and astrocytes (Campbell et al. 1993b; 
Suresha and Srinivasan 2013). Feeding these mice at an age of 2 months with LC and 3 months 
with MCP will downregulate the number and activation state of activated microglia and 
astrocytes. 
2.2 Specific Aims  
 
Aim 1: To investigate if MCP can downregulate the activated higher number of microglia (Iba1, 
TSPO) and astroglial (GFAP) cell numbers in the hippocampus and the cerebellum Inflammation 
in the GFAP-IL6 mouse model. 
Aim 2: To investigate if MCP can reverse the microglia and astroglial cells morphology from the 
activated state to the resting state in the hippocampus and the cerebellum in the GFAP-IL6 
mouse model. 
Aim 3: To investigate if LC can downregulate the activated higher number of microglia (Iba1, 
TSPO) and astroglial (GFAP) cell numbers in the hippocampus and the cerebellum.in the GFAP-
IL6 mouse model. 
Aim 4: To investigate if LC can reverse the microglia and astroglial cells morphology from the 
activated state to the resting state in the hippocampus and the cerebellum in the GFAP-IL6 
mouse model. 
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3. Materials and methods 
 
3.1. Materials  
 
3.1.1. Preparation of curcumin containing food pellets 
 
3.1.1.1 Meriva  
 
MCP was prepared using phytosome technology. The curcumin was supplied by Indena SpA, 
Italy and the MCP curcumin food pellets were prepared locally. Briefly, the food pellets 
consisted of 1:2 weight ratio of curcumin and soy lecithin with overall 20% of curcumin content 
in the final product and two parts of microcrystalline cellulose are then added to improve 
followability and bioavailability. 
 
3.1.2.1 Longvida  
 
 Similarly, LC was prepared using solid lipid curcumin particle technology. Briefly, curcumin 
powder was supplied by Vendure science, USA and LC food pellets were prepared locally. 
Briefly, the curcumin powder was mixed with phosphatidylcholine, vegetable stearic acid, 
ascorbic acid (vitamin C) Palmitate, and other inert ingredients with 20% curcumin (Nahar, Slitt, 
and Seeram 2015). 
 
Table.2. MCP and LC doses 
 
 
Amount in grams of MCP/LC per 
Kg of finished feed 
Dose(s) in mg/kg bw Dose(s) in ppm 
1. MCP 4.37g 35mg/kg/bw 320ppm 
2. MCP 2.18g 70mg/kg/bw 636ppm 
3. MCP 1.09g 140mg/kg bw 1272ppm 
4. LC 2.5g 51-60mg/kg bw 500ppm 
5. NC 0.87g 140mg/kg bw 1272ppm 
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3.2. Animals  
 
3.2.1 Housing and ethics 
 
WT (C57BL/6) and GFAP-IL6 heterozygous mice of mixed genders weighing 20-30g were 
housed in the animal facility of the School of Medicine, Western Sydney University under a 
temperature-controlled environment, with a normal 12h/12 h light/dark cycle at 23 ˚C, 60 ± 10% 
humidity, and provided with food and water ad libitum. The experimental procedures were 
approved by the Western Sydney University Animal Care and Ethics Committee (A11393) and 
carried out in accordance with the rules established by the National Health and Medical Research 
Council of Australia. Heterozygous GFAP-IL6 mice and their non-transgenic littermates (WT 
C57BL/6) were used at the age of 3 months. 
3.2.2. Grouping of animals and feeding with MCP food pellets  
 
Animals were randomly assigned to 6 groups: WT C57BL/6 mice fed with control food pellets 
and GFAP-IL6 mice fed with control food pellets as well. The rest of the four groups of GFAP-
IL6 mice were fed with food pellets containing 140mg/kg bw/d, 70mg/kg bw/d, or 35mg/kg 
bw/d of MCP, 140mg/kg bw/d of normal curcumin (Table 3). At the age of 3 months, the mice 
were fed for one month. The weight of the mice was monitored throughout the feeding period In 
addition, the cage food trays were monitored weekly and noticed that each mouse was eating 3-4 
g/day of the food pellets. At the age of 4 months, they were perfused for histology. 
3.2.3 Grouping of animals and feeding with LC food pellets  
 
In this long term feeding study, animals were randomly assigned to 4 groups: Wild type 
C57BL/6, GFAP-IL6 mice fed with control food pellets and GFAP-IL6, GFAP-IL6 mice fed 
with LC diet (Table 2). The Longvida® curcumin food pellets were supplied by Verdure 
Sciences Corp.; Noblesville, IN. The pellets consisted of natural antioxidant curcumin with 
enhanced followability and bioavailability. At the age of 2 months, the mice were put on feeding 
at one defined dose for the duration of 6 months. Animals were monitored, body weight and the 
amount of food consumed was recorded. It was observed that the mice were constantly gaining 
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weight during the entire feeding tenure. At the age of 8 months, the behavioral test was 
performed followed by perfusion for histology. 
 
Table. 3 Cohort information and the number of mice used 
 
 
Figure 7. Graphical representation of age and feeding differences between the MCP and the LC feeding 
paradigms.  
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3.2.4. Histology and tissue sample preparation 
 
For histological analysis, the tissue samples were prepared from all experimental cohorts. Mice 
were anesthetized with Pentobarbitone (30-50 mg/kg bw IP (20-40 min. of anesthesia) and 
transcardially perfused with 30 ml of 0.9 % normal saline using a peristaltic pump, followed by 
60 ml of 4 % cold paraformaldehyde (Merck) (in 0.1 M phosphate buffer). Brains were harvested 
and post-fixed in 4 % paraformaldehyde for 24 hrs at 4 °C, and then transferred to 30% sucrose 
(in 0.1 M PB solution) for cryoprotection. After the brains sank to the bottom of the container, 
they were embedded and frozen with 6% gelatine. Forty μm thick coronal sections were cut in 
eight series using a Leica CM 1950 cryostat.  
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3.2.5. Immunohistochemistry  
 
For bright field microscopy, immunohistochemistry assays were performed on every 8th section 
from the brains to identify microglial activation using microglia markers (Iba-1 and TSPO). All 
washing and incubation procedures were performed using 0.1M PBS unless stated otherwise. 
The sections were washed 3 times and treated with 1 % H2O2 before being incubated for 2 hrs in 
the blocking solution (2% goat serum) to block non-specific antigen binding sites. Then they 
were incubated in the primary rabbit-anti-Iba1 antibody (1:500, Wako, # 019-19741) and rabbit 
anti TSPO (1:500, Merck, #ABC139) solutions for two days at 4 ˚C and subsequently in the 
secondary antibody (1:200, biotinylated goat anti-rabbit IgG; Life Technologies, #656140) for 2 
hrs. The sections were washed 3 times and ABC solution (1:250, Vector Laboratories, # PK-
6100) was applied for 2 hrs. Sections were then incubated in the developer solution containing 
0.4 mg/ml DAB and 0.0006% hydrogen peroxide until an optimal color developed. In the end, 
the sections were washed, mounted, dehydrated, coverslipped and images were captured with a 
Zeiss microscope (MBF Bioscience). 
 
3.3. Microscopy and anatomical data analysis 
 
3.3.1 Fluorescence microscopy 
 
Immunofluorescent staining against GFAP was performed on every 8th section from the brains 
to identify astroglial activation using GFAP as an astroglial marker. The sections were washed 
with 0.1M PBS in order to remove the gelatine and incubated in the primary rabbit-anti-GFAP 
antibody (1:500, Dako, #20023331) solution for one day at 4 ˚C followed by fluorescence 
secondary antibody (1:200, goat anti-rabbit IgG, Alexa 488; Thermo Fisher Scientific, # 
1853312) for 2 hrs. The sections were washed, mounted and coverslipped with a fluorescent 
mounting medium (Vector Laboratories, #H1400).  
3.3.2. Stereological counting 
 
In order to do the stereological quantification, the estimated number of glial cells in both the 
cerebellum and the hippocampus was counted on Iba1, TSPO and GFAP stained sections using 
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the Zeiss AxioImager M2 microscope equipped with MBF Biosciences StereoInvestigator 
(Bastide et al. 2014; Morgan et al. 2014). Briefly, the objective for the contour of the cerebellum 
and hippocampus was first drawn under the 2.5x objective. The size of the counting frame was 
130 x 130 μm for WT for cerebellum while, 120 x 120 μm for the hippocampus, 60 x 60 μm for 
GFAP-IL6 non-fed mice as well as for MCP fed mice. The counting grid was 1500 x 1000 μm 
for the cerebellum and 800 x 800 μm for the hippocampus for the entire cohorts. The guard zone 
was 1 μm at the top and the bottom of the sections. Microglia and astrocytes were plotted on the 
screen using a marker as the focus moved from the top to the bottom of the sections using a 63x 
oil objective. This led to the Gunderson coefficient error of less than 0.1 in all cases (m=1). The 
average estimated population of the cells has been obtained from each mouse brain Due to 
technical limitations, it was not possible to discriminate between individual astrocytes in the 
cerebellum. Therefore, for this time point, only the representative pictures are shown. However, 
the number of GFAP+ cells in the hippocampus was measured under the above-mentioned 
parameters.  
 
3.3.3. Three-dimensional reconstruction of astrocytes and microglia 
 
Samples were prepared as described above and the images were taken using Confocal ZEISS 
laser Scanning Microscope (LSM-5) with an argon laser and processed using the Zen 2009 
software package. Z-stacks were captured using a 20 x objective, NA1.0 for reflective imaging, 
at a step size of 0.1um (unless specified otherwise). Reflective imaging was achieved using the 
488 nm wavelength. For the three-dimensional reconstruction of both astrocytes and microglia, 
Neurolucida 360 (MBF Bioscience) software was used. To better identify the objects and provide 
greater accuracy, all the images were taken using a 20x high power objective with the laser 
scanning confocal microscope.  A total of 16-20 cells in the hippocampus and the cerebellum of 
the brain were traced in each experimental cohort. The cells and their processes were analyzed in 
three dimensions within single sections by using a computer-based tracing system (Neurolucida 
360; MBF Bioscience, Williston, VT). Only somas were analyzed in two dimensions (area at its 
largest cross-sectional diameter) because of limitations associated with tracing and measuring 
and the cell body area as well as the number, length, diameter, and branching points (nodes) of 
its processes were measured in three dimensions. We further observed thorny protrusions along 
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the length of processes. In order to further assess the spatial distribution of astrocytic processes, a 
3D version of the Sholl analysis (Sholl 1956) was used. 
 
 3.3.4. Analysis of reconstructed cells 
 
Morphometric data of each astrocyte and microglia were extracted by the software and thus, each 
reconstructed cell was subject to multiple parameters. The soma area, soma perimeter, convex 
2D area, convex perimeter, the total length of all processes, the total volume of all processes, 
total density and number of nodes (Branch points) and dendrites of all the processes were 
measured. In order to determine changes in the size of the cell in relation to distance from the 
cell soma, Sholl analysis was performed for each microglial and astroglial cell (Bento-Torres et 
al. 2017). Z-stack images of live microglia and astrocytes were condensed into a maximum 
intensity and applied the Sholl analysis in Neurolucida 360 software. Concentric circles (radii) 
originating from the soma were spaced 5 μm apart in this case. This analysis determined the 
number of intersections, process length (µm), the surface area of the cells (µm2), process volume 
(µm3), process diameter (µm) and a number of nodes of the cells for each radius. 
 
3.3.5 Data analysis 
 
The estimated number of microglia and astrocytes in both the cerebellum and the hippocampus 
were compared between groups using one-way ANOVA in GraphPad Prism 6. Results were 
presented as mean ± SEM. Significance was indicated when p was less than 0.05. Distinct 
morphological features of microglia and astrocytes in the brain were compared between groups 
using One-way ANOVA with Turkey’s post-test (*p < 0.05, **p < 0.001, ***p < 0.0001, mean ± 
SEM). Correlations of the Convex Hull Area with distinct morphological features of microglia 
and astrocytes were analyzed using linear regression (R2) and correlation (*p < 0.05) tests in 
GraphPad Prism 7. ANCOVA test was used to compare slope differences in each specific 
morphological feature (*p < 0.05) between different experimental cohorts. 
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4. RESULTS 
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4.1. Effect of Meriva® curcumin phytosome on microglia and 
astrocytes numbers in the GFAP-IL6 mouse model 
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4.1.1. Introduction 
 
Neuroinflammation is a defense response of the central nervous system to injury, infection or 
toxic metabolites. Acute neuroinflammation is a self-protective reaction aimed at eliminating 
deleterious stimuli and restoring tissue integrity.  However, if neuroinflammation becomes 
chronic it can be harmful. Chronic neuroinflammation is both a feature and a potential cause of 
many neurodegenerative diseases like AD and dementia (Arends et al. 2000). Interleukin 6 (IL-
6) is a multifactorial, regulatory cytokine that may play a pathogenic role in dysregulating 
inflammatory responses (Akira et al. 1990). Microglia and astrocytes play a key role in the 
CNS’s innate immunity. The major role of microglia is to clear damaged neurons and foreign 
pathogens, while astrocytes help to remove debris and toxins from the cerebrospinal fluid. When 
activated, microglia produces a variety of pro-inflammatory cytokines and neurotoxic factors, 
such as reactive oxidative species (ROS), leading to neuronal damage, neuroinflammation and 
subsequent cognitive deficits (Rosenblat et al. 2014; Heneka, Golenbock, and Latz 2015). 
Microglial cells are the key neuroinflammatory cells as they are activated in response to brain 
inflammation and release ROS as well as cytokines that cause neurotoxicity (Block, Zecca, and 
Hong 2007b; Beggs and Salter 2007). TSPO is a translocator protein expressed in the nervous 
system, specifically on the outer mitochondrial membrane (Chen and Guilarte 2008). It is 
predominantly expressed in the microglia, astrocytes, neurons and macrophages in the blood 
vessels (Kuhlmann and Guilarte 2000; Wilms et al. 2003). TSPO represents a novel macrophage 
marker, as neurological insults and chronic neuroinflammation induce TSPO expression in the 
nervous system (Casellas, Galiegue, and Basile 2002; Kuhlmann and Guilarte 2000). Astrocytes 
are vital cells of the CNS, playing an important role in coupling neuronal organization to blood 
flow and maintaining, regulating, and altering neuronal synaptic junctions (Zhang and Haydon 
2005). Astrocytes are highly reactive cells respond to adverse neural insults, such as 
neuroinflammation, trauma, and neurodegeneration (Sofroniew 2009).  Previous studies 
conducted on GFAP-IL6 mice have shown a larger number of GFAP+ astrocytes in both the 
cerebellum and cortical areas compared to WT mice (Chiang et al. 1994). 
GFAP-IL6 mice have been used in this study as a chronic glial cell activation mouse model. In 
the GFAP-IL6 mouse model, the murine IL-6 gene is expressed by astrocytes under the 
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transcriptional control of the glial fibrillary acidic protein (GFAP) promoter, results in brain-
specific overexpression of IL6 and chronic neuroinflammation. This has been demonstrated via a 
significant increase in Iba-1+, TSPO+ microglia, GFAP+ astroglia, and neurodegeneration mostly 
in the cerebellum (Campbell et al. 1993a). This model presents with prolonged 
neuroinflammation (activation of microglia and microgliosis) (Gyengesi et al. 2018) and a range 
of structural and functional neurological impairments, which typify various neurodegenerative 
diseases (Campbell et al. 1993a). Previous studies have reported that GFAP-IL6 transgenic mice 
display a high level of IL6 expression in the cerebellum compared to other brain regions 
(Campbell et al. 1993a; Quintana et al. 2009). A recent study conducted by our lab in the same 
animal model has confirmed that the number of Iba-1+ cells in GFAP-IL6 mice is significantly 
larger compared to that of the WT mice (Gyengesi et al. 2018). This is the first study to evaluate 
the effect of a high bioavailability curcumin formulation MCP curcumin in the GFAP-IL6 mouse 
model. MCP could be a potential suppressive agent against chronic neuroinflammation through 
the modulation of astroglial and microglial activity. To determine how MCP affects the number 
of activated (Iba-1+, TSPO+) microglia and activated (GFAP+) astroglia in the brain, 
stereological counting, were applied to assess the number activated microglia and astrocytes in 
the hippocampus and the cerebellum in an unbiased manner. 
 
4.1.2. Results 
 
4.1.2.1 Curcumin formulations decreased the number of Iba-1+ microglia in the 
hippocampus of GFAP-IL6 mice 
 
First, the phenotype difference between WT and GFAP-IL6 mice and the effect of MCP and 
normal curcumin on the elevated number of Iba-1+ microglial cells in the GFAP-IL6 mice was 
determined. Immunohistochemistry and stereological counting of Iba-1+ microglia were 
performed in the hippocampus in GFAP-IL6 mice fed with normal food, increasing doses of 
MCP and normal curcumin.  
The hippocampus of GFAP-IL6 mice fed with normal food had 438,550 ± 29,717 Iba-1+ 
microglia, which was significantly higher than that of the WT mice (175,192 ± 12,098) (Fig 8A-
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B, G). In the MCP fed GFAP-IL6 mice, a reduction in the number of Iba-1+ microglia was 
observed. The low doses 35mg/kg bw/d and 70mg/kg bw/d of MCP reduced the number by 
17.5% (361,644 ± 54,484) and 22% (338,483 ± 81,353) (Fig 8C-D,G), whereas, 140mg/kg bw/d 
of MCP significantly reduced the number of microglia by 26.2% (323,451 ± 21,520) compared 
to the GFAP-IL6 normal food fed cohort (Fig 8 E,G). In contrast, the 140 mg/kg bw/d normal 
curcumin decreased the number of microglia by 18.3% (357,955 ± 26,079) compared to GFAP-
IL6 normal food fed cohort (Fig 8F, G). 
 
 
 
Figure 8. Curcumin formulations decreased the number of Iba-1+ microglia in the hippocampus of GFAP-IL6 
mice. (A-F) Representative photomicrographs of immunohistochemical staining for the microglia (Iba-1+ cells) of 
the hippocampus. (Magnification 10x objective field, scale bar = 500µm and 100µm in inserts). Images are 
representative of at least six animals per group (n=6). (G) Graphical representation of total Iba-1+ count in the 
hippocampus. The graph represents the mean ± SEM and significant differences were determined using a one-way 
analysis of variance (ANOVA). Significance = ****p < 0.0001, *p < 0.05.   
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4.1.2.2 Curcumin formulations decreased the number of Iba-1+ microglia in the cerebellum 
of GFAP-IL6 mice 
 
In the cerebellum, GPAP-IL6 mice had 1025205 ± 104467 Iba-1+ microglia which was 
significantly higher than that of WT mice (154,058 ± 12,871) (Fig 9A-B, G).  A significant 
reduction in the total number of microglial cells was observed in high dose of MCP and normal 
curcumin groups compared to the normal food fed GFAP-IL6 group. GFAP-IL6 mice fed with 
140mg/kg MCP and 140mg/kg normal curcumin significantly downregulated the Iba-1+ 
microglia by 40% (605,085 ± 63,857) and 38% (629,122 ± 54,363), respectively (Fig 9 E – F, 
G). Whereas, in case of 35mg/kg and 70mg/kg doses of MCP, the Iba-1+ microglial reduced by 
32% (693,938 ± 117,878), 42% (592,373 ± 48,489) , respectively (Fig 9 C – D, G). 
No significant difference in the number of Iba-1+ microglia was observed between 140mg/kg 
bw/d MCP and 140mg/kg bw/d normal curcumin in either brain region. 
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Figure 9. Curcumin formulations decreased the number of Iba-1+ microglia in the cerebellum of GFAP-IL6 
mice. (A-F) Representative photomicrographs of immunohistochemical staining for the microglia (Iba-1+ cells) of 
the cerebellum. (Magnification 10x objective field, scale bar = 500µm and 100µm in inserts). Images are 
representative of at least six animals per group (n=6). (G) Graphical representation of total Iba-1+ count in the 
cerebellum. The graph represents the mean ± SEM and significant differences were determined using a one-way 
analysis of variance (ANOVA). Significance = ****p < 0.0001.  
 
 
4.1.2.3 Curcumin formulations decreased the number of TSPO+ microglial cells in the 
hippocampus of GFAP-IL6 mice 
 
The mitochondrial translocator protein (TSPO) is expressed in both macrophages and a portion 
of microglia in the brain and has been shown to be upregulated in reactive microglia in 
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inflammation (Mirzaei et al. 2016; Cosenza-Nashat et al. 2009). In addition to Iba-1, 
immunostaining was performed for TSPO as a microglial marker. Stereological quantification 
was performed in order to test whether there is a difference in TSPO+ microglia/macrophages 
between WT and GFAP-IL6 mice, whether MCP changes the number of TSPO+ cells in the 
brains of GFAP-IL6 mice, and to investigate the difference between MCP and normal curcumin 
diet fed mice. 
In the hippocampus, GFAP-IL6 mice had 147,803 ± 46,723 TSPO+ microglia compared to WT 
mice (4,747 ± 3,866)(Fig 10A-B,G). Low doses of MCP such as 35mg/kg and 70mg/kg reduced 
the number of TSPO+ microglia by 16% (123,769 ± 6266) and 19% (119,213 ± 11,229) 
respectively. The 140mg/kg dose of MCP significantly decreased the number by 33% (98,941 ± 
21,413) while, the 140mg/kg normal curcumin decreased the number by 26% (108,323 ± 8124) 
compared to GFAP-IL6 non-fed mice (Fig 10E-F, G). No significant difference was observed 
between 140mg/kg bw/d MCP and 140mg/kg bw/d normal curcumin. 
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Figure 10. Curcumin formulations decreased the number of TSPO+ microglial cells in the hippocampus of 
GFAP-IL6 mice. (A-F) Representative photomicrographs of immunohistochemistry staining for the microglia 
(TSPO+ cells) of the hippocampus. (Magnification 10x objective field, scale bar = 500µm and 100µm in inserts). 
Images are representative of at least six animals per group (n=6). (G) Graphical representation of total TSPO+ 
microglial count in the hippocampus. The Graph represents the mean ± SEM and significant differences were 
determined using a one-way analysis of variance (ANOVA). Significance = *p <0.01, ****P < 0.0001.  
 
4.1.2.4 Curcumin formulations decreased the number of TSPO+ microglial cells in the 
cerebellum of GFAP-IL6 mice 
 
In the cerebellum, GFAP-IL6 mice had 369,963 ± 152,991 TSPO+ microglia, which was 
significantly higher than that of WT mice (12,402 ± 8820) (Fig 11A-B,G). Lower doses of MCP 
such as 35mg/kg and 70mg/kg reduced the number of TSPO+ microglia by 26% (276,303 ± 
40,166) and 24% (278,235 ± 35,052) respectively (Fig 11C-D). The 140mg/kg MCP reduced 
TSPO+ microglial number by 42% (215,912 ± 80,444) whereas, 140mg/kg normal curcumin 
reduced the number only by 34% (242,110 ± 12,527) compared to GFAP-IL6 normal food fed 
mice (Fig 11E,F-G).   
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Figure 11. Curcumin formulations decreased the number of TSPO+ microglial cells in the cerebellum of 
GFAP-IL6 mice. (A-F) Representative photomicrographs of immunohistochemistry staining for the microglia 
(TSPO+ cells) of the cerebellum. (Magnification 10x objective field, scale bar = 500µm and 100µm in inserts). 
Images are representative of at least six animals per group (n=6). (G) Graphical representation of total TSPO+ 
microglial count in the cerebellum. The Graph represents the mean ± SEM and significant differences were 
determined using a one-way analysis of variance (ANOVA). Significance = *p <0.01, ****P < 0.0001.  
 
4.1.2.5 Curcumin formulations decreased GFAP+ astrocytes in the hippocampus of GFAP-
IL-6 mice 
 
To quantify the number of astrocytes, GFAP immunostaining and stereological quantification 
were performed to investigate the genotype difference between WT and GFAP-IL6 mice. 
Furthermore, the effect of MCP and normal curcumin on the elevated number of GFAP+ 
astrocytes in the GFAP-IL6 mice was investigated in the hippocampus and cerebellum.  
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In the hippocampus, GFAP-IL6 mice had a significantly larger number of GFAP+ astrocytes 
(530,374 ± 30,447) compared to WT mice (169,908 ± 17,046) (Fig 12A-B,G). In MCP fed 
GPAP-IL6 mice, a significant reduction in the number of GFAP+ astrocytes were observed in a 
dose-dependent manner compared to the GFAP-IL6 normal fed group. MCP at a dose of 
35mg/kg and 70mg/kg reduced the number by 30% (369,401 ± 64,227) and 37% (333,646 ± 
85,311) respectively (Fig 12C-D, G). The 140mg/kg downregulated the total GFAP+ astrocytes 
by 42% (304,668 ± 62,649) whereas, the normal curcumin decreased the number by 25% 
(395,739 ± 23,531) (Fig 12E-F, G) Based on this stereological data, a dose-response curve was 
plotted showing that the IC50 value for MCP is 46.70mg/kg bw in the hippocampus of GFAP-IL6 
mice (Fig 12H).  
 
 
Figure 12. Curcumin formulations decreased GFAP+ astrocytes in the hippocampus of GFAP-IL-6 mice. (A-
F) Representative photomicrographs of immunofluorescence staining for the astrocytes (GFAP+ cells) in the 
hippocampus. (Magnification 5x, scale bar=100µm in 5x and 50µm in inserts). Images are representative of at least 
52 
 
six animals per group (n=6). (BG) Graphical representation of total GFAP count in the hippocampus. The Graph 
represents the mean± SEM and significant differences were determined using a one-way analysis of variance 
(ANOVA). Significance = *p <0.05, **p <0.001, ***P <0.0001, ****p < 0.0001. (H) A dose-response curve 
showing the percentage decrease in a number of astrocytes against log dose concentration (mg/kg) of MCP in the 
hippocampus  
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4.1.2.6 Curcumin formulations decreased GFAP+ astrocytes in the cerebellum of GFAP-IL-
6 mice 
 
In the cerebellum, the astrocytes and their processes were very abundant and densely packed, 
making stereological counting difficult, hence the numbers of GFAP+ cells were not analyzed. 
However, high-level expression of GFAP protein was observed in GFAP-IL6 mice compared to 
WT mice, located mostly but not exclusively in the gray matter of the cerebellum, with a strong 
presence of elongated microglia in the white matter and molecular layer. The difference in the 
distribution of astrocytes between the WT and GFAP-IL6 animals was substantial. No 
conclusions could be drawn in the absence of quantitative stereology. (Fig 13).  
 
Figure 13.Effect of curcumin formulations on  the GFAP+ astrocytes in  the cerebellum of GFAP-IL-6 mice. 
Representative photomicrographs of immunofluorescence staining for the astrocytes (GFAP+ cells) in the 
cerebellum. (Magnification 5x, scale bar=100µm in 5x and 50µm in inserts). Images are representative of at least six 
animals per group (n=6). 
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Table 4. Stereological counting summary of the Iba-1, TSPO positive microglia in the 
hippocampus and the cerebellum and GFAP positive astrocytes in the hippocampus. All 
values are presented as mean ± SEM 
 
  
4.1.2.7 Correlation analysis among the Iba-1+ microglia, TSPO+ microglia, and GFAP+ 
astrocytes 
Since the activation of the glial cell were assessed through Iba-1, TSPO and GFAP markers, 
therefore, in order to see whether Iba-1+ microglia correlate with the TSPO+ microglia and 
GFAP+ in WTs, GFAP-IL6 normal fed and GFAP-IL6 fed, the Iba-1+ microglial count was 
plotted against TSPO+ cell count. A strong correlation was observed between the two markers in 
both the cerebellum (R = 0.76, and the hippocampus (R=0.54) (Fig 15A-B). There was also a 
strong correlation between the Iba-1+ microglial number and GFAP+ astrocytes number (R=0.50) 
in the hippocampus (Fig 14C). Additionally, the numbers of TSPO+ microglia and GFAP+ 
astrocytes were also correlated in the hippocampus (R = 0.54) (Fig 14D). 
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Figure 14. Correlation analysis among the Iba-1+ microglia, TSPO+ microglia, and GFAP+ astrocytes. (A) 
Graphical representation of the correlation between Iba-1+ microglia and TSPO+ cells in the cerebellum. The data 
were analyzed using linear regression and correlation. ****p <0.0001, R2=0.58 (n=31) (B) Graphical representation 
of the correlation between Iba-1+ microglia and TSPO+ cells in hippocampus. The data were analyzed using linear 
regression and correlation. **p <0.001, R2=0.29 (n=31) (C) Graphical representation of the correlation between Iba-
1+ microglia and GFAP+ astrocytes in hippocampus. The data were analyzed using linear regression and correlation. 
**p <0.002, R2=0.25 (n=34) (D) Graphical representation of the correlation between TSPO+ microglia and GFAP+ 
astrocytes in hippocampus. The encircled dotes are WT mice. The data were analyzed using linear regression and 
correlation. ****p <0.0001, R2=0.54 (n=30) 
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4.1.3. Summary 
 
Our results indicate that the high dose of highly bioavailable curcumin is able to attenuate the 
chronic neuroinflammation. After feeding the mice with MCP for four weeks, it was 
observed that all three doses of MCP significantly reduced the number of Iba-1+ microglia in 
the cerebellum and the hippocampus, with the high dose of MCP resulting in the most 
significant decrease.  
This study found that the total estimated number of TSPO+ cells was significantly larger in 
the GFAP-IL6 group than that of the WT group in the cerebellum and the hippocampus. The 
140mg/kg of MCP significantly downregulated chronic neuroinflammation in GFAP-IL6 
mice in both the hippocampus and the cerebellum compared to the non-fed group. TSPO is a 
translocator protein that is mainly expressed in microglia, astrocytes and at low levels in 
neurons in diseased brains (Cosenza-Nashat et al. 2009). In a study conducted in mice has 
measured the fluorescence intensity and the number of TSPO+ per 0.1mm2, has reported that 
TSPO expression is elevated in the brain after exposure to an injury or inflammation 
(Bonsack, Alleyne, and Sukumari-Ramesh 2016). This is consistent with our findings which 
showed that the number of Iba-1+ and TSPO+ microglia in GFAP-IL6 mice was significantly 
larger compared to WT mice. 
Additionally, all three doses of MCP significantly decreased the number of reactive 
astrocytes in the hippocampus compared to the GPAP-IL6 control mice. These results 
indicate that the high dose MCP is effective in attenuating neuroinflammation.  
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4.2. Effect of Meriva® curcumin phytosome on the morphological 
characteristics of astroglial cells in the GFAP-IL6 mouse model 
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4.2.1 Introduction 
 
As discussed earlier, microglia and astrocytes play a key role in CNS’s innate immunity. 
Microglial cells are the key neuroinflammatory cells as they are activated in response to brain 
inflammation and release ROS as well as cytokines that cause neurotoxicity (Block, Zecca, and 
Hong 2007b; Beggs and Salter 2007).  
The morphological features are one of the important characteristics of microglial cells. Under 
normal circumstances, the resting microglia continuously scans the nervous system which is 
termed as ramified morphology (Nimmerjahn, Kirchhoff, and Helmchen 2005). During 
inflammatory conditions, the microglial cells have been observed to go into an “activated state” 
characterized by swollen cell body and thick processes and can adopt an amoeboid-like 
morphology termed as “de-ramified microglia” (Davis, Foster, and Thomas 1994). Similarly, the 
astrocytes morphology is also considered as a hallmark for neurodegenerative diseases.  
Astrocytes have bushy or spongiform shapes and fine and delicate processes emerging from the 
soma (Bushong et al. 2002). In neuroinflammation, when astrocytes are activated, they are 
characterized by high-level expression of GFAP and an increase in size and the number of 
processes compared to the non-reactive astrocytes (Silver and Miller 2004; McGraw, Hiebert, 
and Steeves 2001). 
The study represents the effect of a high bioavailability curcumin formulation MCP curcumin on 
the morphology of astroglial cells in the GFAP-IL6 mouse model. To determine how MCP 
affects the morphology of activated (Iba-1+) microglia and activated (GFAP+) astroglia in the 
brain, 3D reconstruction techniques were applied to assess the morphology of reactive and 
nonreactive microglia and astrocytes in the hippocampus and the cerebellum in an unbiased 
manner. 
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4.2.2 Results 
 
4.2.2.1 Effect of curcumin formulations on the morphological characteristics of microglial 
cells in the hippocampus  
 
In order to demonstrate how chronic inflammation affects the morphology of the microglia, we 
analyzed the anatomical features of the Iba-1+ microglia in the WT and GFAP-IL6 animals in the 
hippocampus. Then, to investigate the effects of MCP on microglia morphology, GFAP-IL6 
mice fed with MCP at different doses and normal curcumin at a dose of 140mg/kg bw/d were 
included in the analysis.  
In the hippocampus, a difference between the genotypes was observed, as Iba-1+ microglial cells 
of GFAP-IL6 mice had significantly larger soma areas (66.36 ± 22.63µm2), soma perimeters 
(33.93 ± 8.18µm) and more processes (5.62 ± 1.84) than those of WT mice [soma area (30.005 ± 
13.93µm2), soma perimeter (20.63 ± 5.50µm) and number of processes (3.66 ± 1.36)]. GFAP-
IL6 mice fed with 140mg/kg dose of MCP had significantly decreased soma area (42.55 ± 9.45), 
soma perimeter (25.47 ± 3.44) and increased the number of nodes compared to GFAP-Il6 mice 
on normal food (10.75 ± 3.49) (Fig. 15 A-H, Table 5). The rest of the lower MCP doses and the 
140mg NC did not result in significant changes in any of the measured parameters.  
 
60 
 
 
61 
 
 
62 
 
Figure 15. Effect of curcumin formulations on the morphological characteristics of Iba-1+ microglial cells in 
the hippocampus. (A) Morphological assessment of reactive and nonreactive microglia in the hippocampus. (B-H) 
Microglias in the inflamed mice have significantly larger soma area, soma perimeter and processes compared to the 
WT mice. High dose MCP significantly reduced soma area and soma perimeter compared to GFAP-IL6 mice. 
However, the same high dose MCP significantly increased the number of nodes compared to the GFAP-Il6 mice. It 
has no effect on the convex area, convex perimeter, dendritic length and number of processes.  
 
Sholl analysis, a quantitative analysis to investigate the morphological characteristics, of 
microglial cells from the hippocampus revealed some further variations in morphology between 
WT and GFAP-IL6 normal food fed, GFAP-IL6 MCP fed and normal curcumin-fed mice 
characteristics. In the hippocampus, the microglias of GFAP-IL6 mice have a significantly larger 
surface area, process volume, and process diameter  than that of WT mice. In MCP fed mice, the 
70mg/kg and 35mg/kg significantly reduced the process volume and diameter whereas, 
140mg/kg significantly decreased the process volume and surface area, while it significantly 
increased the number of nodes compared to the microglia of normal fed GFAP-IL6 mice (Fig. 16 
A-F).  
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Figure 16. Effect of curcumin formulations on the morphological characteristics of Iba-1+microglial cells in 
the hippocampus. A Sholl analysis revealed a significant change in the surface area, processes volume and 
processes diameter of microglia between wild type and GFAP-IL6 inflamed microglia both in the hippocampus. (A-
F) MCP retracted processes volume and processes diameter compared to the GFAP-IL6 mice whereas; the normal 
curcumin significantly affected the surface area and a number of nodes.  
 
In the hippocampus, correlation analysis of microglial cell size with each morphological 
characteristic revealed significant correlations with soma area in WT and 70mg/kg, with convex 
perimeter in all cohorts, and with dendritic length in curcumin-treated cohorts, which revealed 
that microglial cells of WT and 70 mg/kg fed groups tended to increase the size of the soma area. 
It also shows that the convex perimeter of the microglia of each cohort increased with the 
increasing size of the cells, whereas, the dendritic length of the microglia of the fed cohorts were 
increased with the overall cell size. Despite these changes, soma area, soma perimeter, nodes and 
number of dendrites of microglia of all treated cohorts remained consistent regardless of the cell 
size (Fig 17, Table 6).  
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Figure 17. Bivariate correlation: MCP effects on morphology are dose-independent in the hippocampus. (A-
F) Different morphological parameters have been plotted against the convex hull area to see the bivariate correlation 
between WT, GFAP-IL6 and between non-treated and treated ones. The statistical analysis has been summarized in 
tables S1. We found that the convex perimeter of both wild type and GFAP-IL6 are significantly correlated whereas, 
treatment with any dose of MCP gave significant correlation and change in the slope of linear correlation of convex 
perimeter and dendritic length in the hippocampus compared to GFAP-IL6 mice. ANCOVA and Sum-of-Square 
tests.  
Table 5. Morphological analysis of Iba-1+ microglia 
 
  H=Hippocampus, C= Cerebellum 
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Table 6. Bivariate correlation of morphological characteristics with overall microglial cell 
size in the hippocampus
 
 
4.2.2.2 Effect of curcumin formulations on the morphological characteristics of microglial 
cells in the cerebellum  
 
In the cerebellum, microglial cells of GFAP-IL6 mice fed with normal food displayed 
significantly larger soma areas (66.64 ± 12.62) and soma perimeters (33.3 ± 2.84)  as compared 
to those of WT mice [microglial soma area (30.03 ± 8.64) and soma perimeter (20.55 ± 0.28)]. In 
MCP fed mice, 70mg/kg MCP also reduced the soma perimeter of the microglia while, 
140mg/kg dose significantly reduced the soma area (42.48 ± 12.69) and soma perimeter (26.3 ± 
6.52), whereas, it significantly increased the convex area (1617.23 ± 617.94), convex perimeter 
(156.31 ± 56.31), and dendritic length of microglia (235.22 ± 35.73) compared to GFAP-IL6 
controls. The 140mg/kg normal curcumin significantly reduced the soma area (Fig. 18 A-H, 
Table 5). The rest of the lower MCP doses did not result in significant changes in any of the 
measured parameters. 
Sholl analysis, of microglial cells from the cerebellum, revealed some further variations in 
morphology. In the cerebellum of GFAP-IL6 mice, the Iba-1+ microglia have a significantly 
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smaller surface area, process volume (0.0008), and process diameter (0.001) compared to 
microglia of WT mice. In MCP fed mice, the 35mg dose significantly downregulated the surface 
area and process volume while, 140mg dose significantly reduced the surface area, process 
volume, and the processing diameter of the microglia compared to the microglia of non-fed 
GFAP-IL6 mice. The 140mg NC also reduced the surface area, process volume, and the diameter 
of the processes (Fig. 19A -F). 
In the cerebellum, some significant correlations were observed between the soma area and 
dendritic length of GFAP-IL6 microglia whereas, additional significant correlations were 
observed in convex perimeter in each cohort, showing that soma area and dendritic length of 
microglia change with the overall cell size, while the convex perimeter increased with the overall 
increase in microglial cells. The remaining perimeter measures had no effect and remained 
consistent regardless of the cell size (Fig 20, Table 7). 
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Figure 18. Effect of curcumin formulations on the morphological characteristics of microglial cells in the 
cerebellum. (A) Morphological assessment of reactive and nonreactive microglia in the cerebellum. (B-H) In the 
cerebellum, microglia in the inflamed mice have significantly high soma area and soma perimeter compared to the 
WT microglia. MCP and normal curcumin both significantly reduced the soma area while, CP high and medium 
dose with the normal curcumin significantly decreased the soma perimeter whereas, only the high dose MCP 
significantly increase the convex area, convex perimeter, and dendritic length compared to the GFAP-IL6 mice. 
One-way ANOVA, Tukey’s post-test, Significance = *p <0.01, ***p < 0.001, ****p < 0.0001. mean ± SEM) 
 
 
 
 
Figure 19: MCP and normal curcumin retract Iba-1+microglia in the cerebellum. A Sholl analysis revealed a 
significant change in the surface area, processes volume and processes diameter of microglia between wild type and 
GFAP-IL6 inflamed microglia both in the cerebellum. (A-F) MCP and normal curcumin retracted surface area, 
processes volume and processes diameter compared to the inflamed microglia. this can be observed in the peaks of 
the distributions of different morphological features being closer to the center compared to wild-type and GFAP-IL6 
mice, we call it X at Ymax. One-way ANOVA test. 
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Figure 20. Bivariate correlation: MCP effects on morphology are dose-independent in the cerebellum. (A-F) 
Different morphological parameters have been plotted against the convex hull area to see the bivariate correlation 
between WT, GFAP-IL6 and between non-treated and treated ones. The statistical analysis has been summarized in 
tables. We found that medium and high doses of MCP showed a significant correlation in convex perimeter 
compared to the GFAP-IL6. ANCOVA and Sum-of-Square tests.  
 
 
 
Table 7. Bivariate correlation of morphological characteristics with overall Iba-1+ 
microglial cell size in the cerebellum 
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4.2.2.3 Effect of curcumin formulations on the morphological characteristics of astrocytes 
in the hippocampus 
 
During inflammation, astrocytes are thought to undergo cellular hypertrophy and increased the 
thickness of their main cellular processes. In order to investigate the difference in morphology of 
the astrocytes between WT and GFAP-IL6 normal food fed mice, GFAP-IL6 normal food and 
different doses of MCP food fed mice, the morphology of astrocytes was characterized in the 
hippocampus. Figure 21 A-F demonstrates the representative images of astrocytes 
immunostained for GFAP in the hippocampus. The astrocytes in the GFAP-IL6 normal food fed 
mice had significantly larger convex area (1247.74 ± 371.77µm2), convex perimeter (142.27 ± 
26.27µm), dendritic length (224.35 ± 66.24µm), and number of nodes (7.33 ± 2.49), when 
compared to astrocytes of WT mice [convex area (601.93 ± 201.46 µm2), convex perimeter 
(95.04 ± 27.79 µm), dendritic length (107.68 ± 29.17 µm) and number of nodes (4.68 ± 1.0)]. In 
contrast, 70mg/kg dose significantly decreased the dendritic length (160.85 ± 30.96 µm) and the 
number of nodes (4.46 ± 1.94) whereas, 140mg fed MCP significantly decreased the convex area 
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(857.27 ± 200.79 µm2) (p <0.02), dendritic length (139.72 ± 32.87µm), and the number of nodes 
(3.86 ± 2.61). (Table 8). 
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Figure 21. Effect of curcumin formulations on the morphological characteristics of astrocytes in the 
hippocampus. (A) 3D reconstruction of astrocytes in WT and GFAP-IL6 in both treated and non-treated mice. (B-
H) Astrocytes in the inflamed mice have a significantly high convex area, convex perimeter, dendritic length and 
nodes compared to WT. High dose MCP significantly decreased the convex area, dendritic length and nodes 
whereas, the medium dose also significantly decreased both the dendritic length and number of nodes compared to 
GFAP-IL6. One-way ANOVA, Tukey’s post-test, Significance = *, **, **** p <0.02, 0.01,0.0001. mean ± SEM) 
 
Furthermore, the morphology of astrocytes was quantified by Sholl analyses. This analysis 
revealed some phenotype differences in the number of intersections, processes length, surface 
area and a number of nodes, which were significantly larger in GFAP-IL6 mice compared to WT 
mice. In addition, it was found that 140mg/kg normal curcumin significantly reduced the number 
of intersections, and both 70mg/kg and 140mg/kg MCP significantly decreased the process 
length. Interestingly, 35mg/kg MCP and 140mg/kg normal curcumin increased the surface area, 
35mg/kg, 70mg/kg and 140mg/kg and normal curcumin increased the process volume and length 
of the processes compared to the non-fed GFAP-IL6 mice. No effects of MCP were observed in 
the number of nodes (Fig 22 A-F). 
  
Figure 22: MCP and normal curcumin increase the ramification of astrocytes in the hippocampus region. (A-
F) A Sholl analysis confirmed a significant increase in the number of the intersection, processes length, surface area, 
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and a number of nodes compared to wild type. In contrast, MCP significantly affects the inflamed astrocytes, which 
is observed in the peaks of the distributions of different morphological features being closer to the center compared 
to wild-type and GFAP-IL6 mice, we call it X at Ymax. One-way ANOVA test. 
 
 
The bivariate correlations of morphological characteristics were performed with overall 
astroglial cell size to investigate the impact of the size of astroglial cells on the structural 
parameters. Some positive correlations of the astroglial cell size with morphological parameters 
were observed. Soma area and soma perimeter of astrocytes in the 35mg/kg CP group changed 
significantly with the overall change in the entire cells. The convex perimeter and dendritic 
length of all cohorts changed with the overall changes in astrocytes. It was also observed that the 
number of nodes in the astrocytes of 35mg/kg and 140mg/kg fed cohorts decreased when the 
overall size of the astrocytes decreased. In the case of primary dendrites, both the 70mg/kg and 
140mg/kg doses positively decreased them with the decrease in the overall cell size of astrocytes 
(Fig 23, Table 9). Taken together, this study has revealed that the 140mg MCP decreased the 
activation and reduced the size of astrocytes, to a measure that is comparable to those seen in the 
WT brain. 
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Figure 23. Bivariate correlation: MCP effects on astrocytes morphology are dose-independent in the 
hippocampus. (A-F) Different morphological parameters have been plotted against the convex hull area to see the 
bivariate correlation between WT, GFAP-IL6 and between non-treated and treated astrocytes which is summarized 
in Table S3. The analysis revealed that the convex perimeter and dendritic length are significantly correlated 
irrespective of the MCP dose. Whereas, in the case of a low dose of MCP, soma area, soma perimeter and nodes 
while the primary dendrites in medium dose, are significantly correlated compared to the GFAP-IL6 mice.  
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Table 8. Morphological analysis of GFAP+ astrocytes in the hippocampus 
 
 
 
 
 
 
 
 
 
Table 9. Bivariate correlation of morphological characteristics with overall astroglial cell 
size in the hippocampus 
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4.2.3 Summary 
 
Overall, our results indicate that the 140mg/kg dose of MCP is able to reverse microglial and 
astroglial activation. The healthy, diseased and MCP treated microglial morphology were 
characterized, which revealed certain characteristics of microglia not reported elsewhere. The 
present study has identified that the microglial soma area and soma perimeter significantly 
increased in both the hippocampus and cerebellum of GFAP-IL6 mice compared to those of the 
healthy controls. Additionally, there was a significantly larger number of processes in the 
microglia of the inflamed brains compared to normal brains. MCP altered the morphology of the 
microglial cells by reducing soma area and soma perimeter. The high dose MCP significantly 
reduced the soma area and soma perimeter, while it significantly increased the number of nodes 
in the hippocampus. In the cerebellum, the high dose MCP significantly reduced the soma area 
and soma perimeter while it increased the convex area, convex perimeter, and dendritic length 
compared to the non-fed control. Interestingly, the morphology of microglia in the 140mg NC 
GFAPIL6 mice was also affected, as soma area and soma perimeter was significantly decreased 
in the cerebellum of GFAP-IL6 mice. In short, the MCP modified morphology towards that of 
microglia in the normal mice.  
Herein, morphological investigations of astrocytes in the hippocampus have shown that 
astrocytes of GFAP-IL6 mice have significantly longer dendritic length compared to that of WT 
mice, and the high and medium dose of MCP significantly decreased the dendritic length. 
Moreover, the convex area of the inflamed astrocytes was also significantly larger than that of 
WT type mice cells, and the high dose MCP significantly decreased the convex area. Astrocytes 
are activated in response to CNS challenges such as trauma, infections, and neuroinflammatory 
diseases, and this activation is considered as a hallmark of neurodegeneration. They have a bushy 
structure with tiny fine processes connected with synapses. Once they are activated, the reactive 
astrocytes undergo morphological changes relative to the resting cells, wherein cellular processes 
extend (Wilhelmsson et al. 2006; Grosche et al. 1999). Emerging studies have reported that 
curcumin can inhibit the hypertrophy of astrocytes in the CNS. One of the studies has reported 
that curcumin formulation has slightly decreased the astrocyte activation and the number of 
branches in the hippocampus. Similarly, another study conducted in rats using a trumatic brain 
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injury model reported a decrease in hypertrophy of astrocytes after been treated with curcumin 
(Ji et al. 2013; Maiti, Paladugu, and Dunbar 2018).  
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4.3. Effect of Longvida curcumin on microglia and astrocyte 
numbers in the GFAP-IL6 mouse model 
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4.3.1 Introduction 
 
Chronic microglial activation describes the chronic, CNS-specific, inflammation-like glial 
responses that do not reproduce the classic characteristics of inflammation but cause 
neurodegeneration (Block and Hong 2007). Microglia and astrocytes play a key role in the 
CNS’s innate immunity. The role of microglia is to clear the damaged neurons and may control 
the pathological processes to maintain the homeostasis of the CNS (Suzumura 2017) while, 
astrocytes help to remove debris and toxins from the cerebrospinal fluid (Heneka, Golenbock, 
and Latz 2015). The inflammatory response is mediated by the activated microglia, which is 
considered as the hallmark of neuroinflammation. The chronic activation of microglia leads to 
neuronal damage through the release of various cytotoxic molecules such as cytokines, reactive 
oxygen intermediates, proteinases (Heneka et al. 2015). TSPO is a mitochondrial translocator 
protein predominantly expressed in the microglia, astrocytes, and macrophages in the blood 
vessels in the nervous system, specifically on the outer mitochondrial membrane (Chen and 
Guilarte 2008), (Kuhlmann and Guilarte 2000; Wilms et al. 2003). 
Curcumin, obtained from the dry rhizome of Curcuma longa Linn, targets multiple 
chemotherapeutic and inflammatory pathways and has demonstrated safety and tolerability in 
animal and humans, supporting its potential as a therapeutic agent; however, the pre-clinical and 
clinical literature lacks conclusive evidence supporting its use as a therapeutic agent due to its 
low bioavailability in humans (Gota et al. 2010). Therefore, the SLCP preparation, LC, patented 
by Verdure Sciences (Noblesville, IN, USA) has the potential to enables the uptake of free 
curcumin to the blood and target tissues. It has been reported that LC has comparatively high 
bioavailability and absorption compared to the unformulated curcumin. A study conducted in 
mice which have revealed that LC has the to cross the blood-brain barrier when orally 
administered, where it was reported to reach concentrations four times greater than that of 
unformulated curcumin (Begum et al. 2008b). Clinical studies conducted to compare the 
pharmacokinetics and bioavailability of free curcumin and LC in humans. The study has 
confirmed that the mean peak concentration of curcumin achieved from dosing 650 mg of LC 
was 22.43 ng/mL, whereas plasma curcumin from dosing an equal quantity of unformulated 95% 
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curcuminoids extract was not detected (Gota et al. 2010). The present study sought to investigate 
the effects of LC on microglia and astroglia numbers in the GFAP-IL6 mouse. 
 
4.3.2. Results 
 
4.3.2.1. LC decreased the microglia numbers in the hippocampus  
 
In order to test the genotype difference between wild type and GFAP-IL6 normal food fed mice, 
and the effect of LC on the microglial number in both wild type and GFAP-IL6, 
immunohistochemistry and stereological counting of Iba-1+ microglia were performed in the 
hippocampus in control and LC fed cohorts.  
Using two way ANOVA on our cohorts, a significant difference was found between the groups 
[F(3,16) = 35.10] in the hippocampus. In the hippocampus, the wild type mice had 184,706 ± 
19,037 Iba-1+ microglia, which was slightly decreased by (16.53%) in wild type LC fed mice 
(156,498 ± 10,762) (Fig 24 A-B, E). In contrast, the GFAP-IL6 mice had 383,588 ± 12,253 Iba-
1+ microglia, which was significantly reduced to 295,666 ± 31,017 (25.88%) in LC fed mice (Fig 
24 C-E).  
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Figure 24. LC decreased the microglia numbers in the hippocampus. (A-D) Representative photomicrographs 
of immunohistochemical staining for the microglia (Iba-1+ cells) of the hippocampus. (Magnification 10x objective 
field, scale bar = 500µm and 100µm in inserts). Images are representative of at least six animals per group (n=6).  E. 
Graphical representation of total Iba-1+ count in the hippocampus. The graph represents the mean ± SEM and 
significant differences were determined using a two-way analysis of variance (ANOVA). Significance = **p < 
0.0015 
 
4.3.2.2. LC decreased the microglia numbers in the cerebellum  
 
In order to test the genotype difference between wild type and GFAP-IL6 normal food fed mice, 
and the effect of LC on the microglial number in both wild type and GFAP-IL6, 
immunohistochemistry and stereological counting of Iba-1+ microglia were performed in the 
cerebellum in control and LC fed cohorts.  
In the cerebellum, using two-way ANOVA on our cohorts, a significant difference was found 
between the groups [F(3,23) = 16.72]. The wild type mice had 156,454 ± 33,721 Iba-1+ 
microglia which was slightly, but not significantly increased in wild type LC fed mice (222,026 
± 75,55) (Fig 25 A-B, E). The GFAP-IL6 mice had 847,456 ± 46,120 Iba-1+ microglia, which 
was significantly downregulated by (48%) in LC fed GFAP-IL6 mice (439,038 ± 49,423) (Fig 25 
C-E).  
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Figure 25.  LC decreased the microglia numbers in the cerebellum. (A-D) Representative photomicrographs of 
immunohistochemical staining for the microglia (Iba-1+ cells) of the cerebellum. (Magnification 10x objective field, 
scale bar = 500µm and 100µm in inserts). Images are representative of at least six animals per group (n=6).  E. 
Graphical representation of total Iba-1+ count in the cerebellum. The graph represents the mean ± SEM and 
statistical analyses were applied using a two-way analysis of variance (ANOVA).  
 
4.3.2.3. LC downregulated the number of TSPO+ cells in GFAP-IL6 mice in the 
hippocampus  
 
In order to investigate the genotype difference between the wild type and GFAP-IL6 normal food 
fed mice, and to test the effect of LC on TSPO+ microglia in both wild type and GFAP-IL6 mice, 
immunohistochemistry and stereological counting of the TSPO positive microglia/macrophages 
was performed.  
In the hippocampus, using two-way ANOVA on our cohorts, a significant difference was 
observed between the groups.[F(3,10) = 30.80, p < 0.0001]. However, using multiple 
comparisons, the wild type mice had 6626 ± 3952 TSPO+ microglia, which were slightly, but 
non-significantly increased by (1.92%) in LC fed wild type mice (6755 ± 1730) (Fig 26 A-B). In 
contrast, GFAP-IL6 had 236, 098 ± 28,005 TSPO+ microglia, which were reduced by 24.46% in 
LC fed GFAP-IL6 mice (184,624 ± 23,174) (Fig 26 C-E). 
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Figure 26. LC downregulated the number of TSPO+ cells in GFAP-IL6 mice in the hippocampus. (A-D) 
Representative photomicrographs of immunohistochemical staining for the microglia (TSPO+ cells) of the 
hippocampus. (Magnification 10x objective field, scale bar = 500µm and 100µm in inserts). Images are 
representative of at least six animals per group (n=6).  E. Graphical representation of total TSPO+ count in the 
hippocampus. The graph represents the mean ± SEM and the percentage differences were determined using a two-
way analysis of variance (ANOVA), p < 0.19. 
 
4.3.2.4. LC downregulated the number of TSPO+ cells in GFAP-IL6 mice in the cerebellum 
 
In order to investigate the genotype difference between the wild type and GFAP-IL6 normal food 
fed mice, and to test the effect of LC on TSPO+ microglia in both wild type and GFAP-IL6 mice, 
immunohistochemistry and stereological counting of the TSPO positive microglia/macrophages 
was performed in the cerebellum.  
In the cerebellum, using two-way ANOVA on our cohorts, a significant differenence were found 
between the groups. [F(3,10) = 23.89]. Using multiple comparisons, wild type mice had 18,108 ± 
2933 TSPO+ microglia, which were slightly decreased (by 5.73%) in LC fed wild type mice 
(17,098 ± 4161) (Fig 27 A-B). Whereas, GFAP-IL6 mice on normal diet had 364,942 ± 28,577 
TSPO+ cells, which was significantly downregulated by 31.37% in the LC fed GFAP-IL6 group 
(265,979 ± 55,791)) (Fig 27, C-E). 
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Figure 27. LC downregulated the number of TSPO+ cells in GFAP-IL6 mice in the cerebellum. (A-D) 
Representative photomicrographs of immunohistochemical staining for the microglia (TSPO+ cells) of the 
cerebellum. (Magnification 10x objective field, scale bar = 500µm and 100µm in inserts). Images are representative 
of at least six animals per group (n=6).  E. Graphical representation of total TSPO+ count in the cerebellum. The 
graph represents the mean ± SEM and significant differences were determined using a two-way analysis of variance 
(ANOVA). Significance = ***p < 0.005 
 
 
4.3.2.5. LC decreased the number of GFAP+ astrocytes in the hippocampus  
 
In order to quantify the number of astrocytes, GFAP immunostaining and stereological 
quantification were performed to investigate the genotype difference between WT and GFAP-
IL6 normal food fed mice. Furthermore, the effect of LC on the elevated number of GFAP+ 
astrocytes in the wild type GFAP-IL6 mice was investigated in the hippocampus and cerebellum.  
In the hippocampus, GFAP-IL6 mice had a significantly larger number of GFAP+ astrocytes 
(372,850 ± 36,861) compared to WT mice (211,968 ± 11,730)) (Fig 28A-B). In LC fed WT 
mice, the astrocytes number reduced by 23% (161,441 ± 19,648) whereas, In LC fed GFAP-IL6 
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mice, a significant reduction in GFAP+ astrocytes were observed by 30% (264,105 ± 24,115) 
compared to the GFAP-IL6 normal food fed mice (Fig 28, C-E). 
 
Figure 28. LC decreased the number of GFAP+ astrocytes in the hippocampus. (A-D) Representative 
photomicrographs of immunofluorescence staining for the astrocytes (GFAP+ cells) in the hippocampus. 
(Magnification 5x objective field, scale bar=100µm in 20x and 20µm). Images are representative of at least six 
animals per group (n=6). (E) Graphical representation of total GFAP count in the hippocampus. The Graph 
represents the mean± SEM and significant differences were determined using a two-way analysis of variance 
(ANOVA). Significance = *p <0.05, **p <0.001 
 
4.3.2.6. Effect of LC on the number of GFAP+ astrocytes in the cerebellum 
 
In the cerebellum, the astrocytes and their processes were very closely packed, making 
stereological counting difficult, hence the numbers of GFAP+ cells were not stereologically 
analyzed. However, high-level expression of GFAP protein was observed in GFAP-IL6 mice 
compared to WT mice, located mostly but not exclusively in the gray matter of the cerebellum, 
with a strong presence of elongated microglia in the white matter and molecular layer. The 
difference in the distribution of astrocytes between the WT and GFAP-IL6 animals was 
substantial. No conclusions could be drawn in the absence of quantitative stereology. (Fig 29 A-
D).  
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Figure 29. The effect of LC on the number of GFAP+ astrocytes in the cerebellum. (A-D) Representative 
photomicrographs of immunofluorescence staining for the astrocytes (GFAP+ cells) in the cerebellum. 
(Magnification 5x objective field, scale bar=100µm in 5x and 20µm in inserts). Images are representative of at least 
six animals per group (n=6). 
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Table 10. Stereological counting summary of the Iba-1, TSPO positive microglia in the 
hippocampus and the cerebellum and GFAP positive astrocytes in the hippocampus. All 
values are presented as mean ± SEM 
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4.3.3. Summary 
 
The purpose of the study was to investigate the therapeutic effects of LC in chronic glial 
activation in the central nervous system. In this study, we have assessed the anti-inflammatory 
effect of LC in GFAP-IL6 mice. The mice were fed for 4 months and the results were compared 
with normal diet fed animals, using both wild type and GFAP-IL6 animals on both diets. 
In summary, our results revealed that LC decreased the Iba1+ microglia numbers by 25.88% in 
the hippocampus and by 48% in the cerebellum, as well as the TSPO+ microglia numbers by 
24.45% in the hippocampus and by 31% in the cerebellum.  These reductions in these activated 
microglia numbers could indicate overall decreased levels of glial activation, meaning an 
improvement in the condition associated with the neuroinflammatory process (Sasaki 2017). 
Moreover, In LC fed GFAP-IL6 mice, a significant reduction in GFAP+ astrocytes were observed 
in the hippocampus by 30% compared to the GFAP-IL6 normal food fed mice. In Cerebellum, 
using qualitative observation and analysis, LC fed groups appeared to have a comparatively low 
expression of GFAP protein compared to the GFAP-IL6 group. 
In short, the long term LC feeding to the mice was able to reduce the chronic microglia and 
astroglial activation in GFAP-IL6 mice compared to the normal food fed mice. 
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4.4. Effect of Longvida curcumin on the glial cell morphology in 
the hippocampus and the cerebellum in GFAP-IL6 mice 
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4.4.1 Introduction 
 
The morphology of microglia and astrocytes is also considered as the key characteristic of the 
progress of neuroinflammation (Kirkley et al. 2017). Microglia are distributed throughout the 
brain in unequal fashion and shape which is evidence that microglial cells are sensitive to the 
surrounding microenvironment (Lawson et al. 1990). Under normal condition, the microglia are 
characterized by ramified morphology such as normal soma with long dendrites and bushy 
shape. However, they are never in a real resting state and constantly scan the surrounding 
environment (Nimmerjahn, Kirchhoff, and Helmchen 2005). During an injury or 
neuroinflammatory assaults, the resting microglial cells go into “activated state” characterized by 
swollen soma, shorter, thick processes and sometimes adopt amoeboid-like morphologies termed 
as “de-ramified microglia (Kirkley et al. 2017) (Sierra et al. 2013; Davis, Foster, and Thomas 
1994).  
Astrocytes are the most abundant cell type of the CNS, playing a major role in brain 
homeostasis, provide metabolites and growth support to neurons synapse formation and plasticity 
and regulate the extracellular balance of ions and fluids (Colombo and Farina 2016). The resting 
astrocytes are thought to exhibit an intricate bushy or spongiform morphology, and they have 
fine processes (Bushong et al. 2002). Astrocytes are activated in respond to neural insults, such 
as neuroinflammation release cytokines, ILs, NO, and other potentially cytotoxic molecules 
(Ahmad, Fatima, and Mondal 2019; Sofroniew 2009). Astrocytes respond to CNS challenges and 
the activated astrocytes are a hallmark of neuroinflammation which is characterized by high-
level expression of the glial fibrillary acidic protein (GFAP) (Wilhelmsson et al. 2006). 
Astrocytes display a bushy or spongiform morphology with very fine processes (Bushong et al. 
2002). When the astrocytes are activated, they exhibit striking increases in GFAP 
immunoreactivity and in the number and length of GFAP-positive processes (Kimelberg and 
Norenberg 1989). 
The study investigates the effect of LC on the morphology of astroglial cells in the GFAP-IL6 
mouse model. To determine how LC affects the morphology of activated (Iba-1+) microglia and 
activated (GFAP+) astroglia in the brain, 3D reconstruction techniques were applied to assess the 
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morphology of reactive and nonreactive microglia and astrocytes in the hippocampus and the 
cerebellum in an unbiased manner. 
 
4.4.2. Results 
 
 
4.4.2.1 Effect of LC on microglial morphology in the hippocampus  
 
In neuroinflammation or after brain injury, a de-ramification of microglia has been observed. 
Thus, the microglia get into the “activated state” characterized by swollen ramified cells with 
larger some and short dendrites (Davis, Foster, and Thomas 1994). In order to investigate the 
genotype difference and the effect of the LC diet on Iba-1+ microglial cells, we analyzed the 
morphological features of the Iba-1+ microglia in the WT and GFAP-IL6 both normal fed and 
LC fed animals in the hippocampus.  
In the hippocampus, a difference in few parameters between the genotypes was observed, as Iba-
1+ microglial cells of GFAP-IL6 mice normal fed had significantly larger soma areas (57.25 ± 
4.03µm2), small convex areas (1035.60 ± 79.12µm2) and convex perimeter (127.68 ± 4.39µm) 
than those of WT [soma areas (42.57 ± 3.82µm2), convex areas (1535.63 ± 139.68µm2) and 
convex perimeter (155.83 ± 6.11µm)]. In addition, Iba-1+ microglia in WT LC fed mice had a 
significantly larger dendritic length (281.94 ± 21.97µm)  than that of the WT normal fed mice 
(212.90 ± 10.23µm). Whereas, Iba-1+ microglial cells of GFAP-IL6 LC fed mice had 
significantly large dendritic length (266.83 ± 14.10) and number of nodes (9.25±0.59) than that 
of GFAP-IL6 normal fed mice [ Dendritic length (192.16 ± 14.58), number of nodes (6.43 ± 
0.70)] (Fig. 30 A-H, Table 11). 
In order to further the morphological characteristics, of microglial cells from the hippocampus, a 
quantitative analysis termed as Sholl analysis was applied which revealed some further variation 
in morphology between WT and GFAP-IL6 normal fed and LC fed mice. In the hippocampus, 
there was no significant difference between WT and GFAP-IL6 normal fed mice Observed in 
any parameter. Although, the microglia of WT LC fed mice have a significantly larger surface 
area, process volume, and process diameter than that of WT normal fed mice. Whereas, the 
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microglia of LC fed GFAP-IL6 mice have significantly larger processes in length  compared to 
GFAP-IL6 normal fed mice (Fig. 31 A-F).  
 In the hippocampus, correlation analysis of overall microglial cell size with each morphological 
characteristic revealed a significant correlation with soma area, soma perimeter, number of nodes 
and primary dendrites in LC fed GFAP-IL6 mice, which clearly revealed that the microglial cells 
of the GFAP-IL6 LC fed mice potentially increased the overall soma size and dendrites number. 
In addition, the convex perimeter and dendritic length of each cohort increased with the 
increasing size of the entire cell. Whereas, the rest of the parameters in the other cohorts 
remained consistent (Fig 32 A-F, Table 12).  
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Figure 30. Effect of LC on microglial morphology in the hippocampus. (A) The representative images of 
microglia immunostained for Iba-1 in the hippocampus. Scale bar 10µm. (B-H) Graphs showing the morphological 
changes in Iba-1+ microglia. Two-way ANOVA, Tukey’s post-test, mean ± SEM) 
 
 
Figure 31. The effect of LC on microglial cells in sholl analysis in the hippocampus region. (A-F) There was no significant 
difference between WT and GFAP-IL6 normal fed mice in any parameter. WT LC fed mice have a significantly larger surface 
area, process volume, and process diameter than that of WT normal fed mice. Whereas the microglia of LC fed GFAP-IL6 mice 
have significantly larger processes in length, which is observed in the peaks of the distributions of different morphological 
features, we call it X at Ymax. Two-way ANOVA test. 
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Figure 32. Bivariate correlation: LC effects on microglial morphology in the hippocampus. (A-F) Different morphological 
parameters have been plotted against the convex hull area to see the bivariate correlation between WT normal-diet, WT LC-diet 
GFAP-IL6 normal-diet, and GFAP-IL6 LC-diet.  
 
 
4.4.2.2 Effect of LC on microglial morphology in the cerebellum 
 
In order to investigate the genotype difference and the effect of the LC diet on Iba-1+ microglial 
cells, we analyzed the morphological features of the Iba-1+ microglia in the WT and GFAP-IL6 
both normal fed and LC fed animals in the cerebellum.  
In cerebellum, a significant difference was observed in genotype as, Iba-1+ microglial cells of 
GFAP-IL6 mice normal fed had significantly large soma area (77.68 ± 7.89µm2), soma perimeter 
(37.21 ± 2.44µm) and small convex area (1087.96 ± 150µm2) (p < 0.015), convex perimeter 
(137.57 ± 9.45µm) than those of the wild type non-fed mice [soma area (38.82±2.80µm2), soma 
perimeter (24.10 ± 0.82µm) and small convex area (1750.71 ± 148.98µm2), convex perimeter 
98 
 
(171.42 ± 7.98µm). Also, Iba-1+ microglia in WT LC diet had a significantly large dendritic 
length (265.30 ± 21.52µm) than WT normal fed mice (199.55 ± 14.70). Whereas, Iba-1+ 
microglial cells of GFAP-IL6 LC fed mice had significantly reduced soma area (50.18 ± 
4.77µm2), soma perimeter (28.10 ± 1.68µm) and more number of nodes (8.07±1.06) than that of 
GFAP-IL6 normal fed mice [soma area (77.68 ± 7.89µm2), soma perimeter (37.21 ± 2.44µm) 
number of nodes (4.92 ± 0.65)] (Fig. 33 A-H, Table 11). 
In order to further the morphological characteristics, of microglial cells from the cerebellum, a 
quantitative analysis termed as Sholl analysis was applied which revealed some further variation 
in morphology between WT and GFAP-IL6 normal fed and LC fed mice. In the cerebellum, 
there was not any genotype difference between WT and GFAP-IL6 normal fed mice. In WT fed 
mice, the microglial cells have a significantly larger surface area, process volume, and process 
diameter than that of WT normal fed mice (Fig. 34 A-F). 
In the cerebellum, significant correlations were observed in all cohorts in convex perimeter and 
dendritic length with overall cell size, showing that the convex perimeter and the length of 
dendrites increased with the overall increase in microglial cells. Moreover, the numbers of nodes 
in GFAP-IL6 non fed cohorts were increased with the overall increase in microglial cells. The 
other parameter remained consistent across the cohort regardless of the cell size (Fig 35 A-F, 
Table 13). 
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Figure 33. Effect of LC on microglial morphology in the cerebellum. (A) The representative images of microglia 
immunostained for Iba+-1 in the cerebellum. Scale bar 10µm. (B-H) Graphs showing the morphological changes in 
Iba-1+ microglia. Two-way ANOVA, Tukey’s post-test, mean ± SEM) 
 
 
 
 
Figure 34. Effect of LC on microglial cells in sholl analysis in the cerebellum region (A-F) There was not any genotype 
difference between WT and GFAP-IL6 normal fed mice. The microglial cells have a significantly larger surface area, process 
volume, and process diameter than that of WT normal fed mice, Which was observed in the peaks of the distributions of different 
morphological features, we call it, X at Ymax. Two-way ANOVA test. 
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Figure 35. Bivariate correlation: LC effects on microglial morphology in the cerebellum. (A-F) Different morphological 
parameters have been plotted against the convex hull area to see the bivariate correlation between WT normal-diet, WT LC-diet 
GFAP-IL6 normal-diet, and GFAP-IL6 LC-diet. 
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Table 11. Morphological analysis of Iba-1+ microglia 
 
H=Hippocampus, C= Cerebellum 
 
 
Table 12. Bivariate correlation of morphological characteristics with overall microglial cell 
size in the hippocampus 
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Table 13. Bivariate correlation of morphological characteristics with overall microglial cell 
size in the cerebellum  
 
 
4.4.2.3. Effect of LC curcumin on astrocytes morphology in the hippocampus 
 
In inflammation, astrocytes are activated like microglial cells and undergo cellular hypertrophy 
which leads to altering their size and shape. We, therefore, characterized the morphology of 
astrocytes in the hippocampus of wild type normal diet, wild type LC diet, GFAP-IL6 normal-
diet, and GFAP-IL6 LC-diet mice. Figure 36 A-H demonstrates the representative images of 
astrocytes immunostained for GFAP in the hippocampus. In both wild type normal diet and wild 
type LC diet, we observed almost similar astrocytes and there were no significant differences. 
Whereas the astrocytes in the GFAP-IL6 normal-diet mice had a significantly larger dendritic 
length (275 ± 17.8µm), a number of processes (6.06 ± 0.51), convex area (1418 ± 128.3µm2), 
convex perimeter (147.9 ± 6.01µm) and a number of nodes (7.62 ± 0.77) compared to the wild 
types. The LC diet significantly decreased the dendritic length (175.2 ± 14.54µm), number of 
processes (4.06 ± 0.23), convex area (968.3 ± 74.04µm2), convex perimeter (125.8 ± 4.24µm), 
and number of nodes (5.43 ± 0.56) (Fig 36 A-H, Table 14). 
Furthermore, we quantified the astroglial cells by Sholl analyses. In the same manner, this 
analysis didn’t reveal any significant changes between wild type normal-fed and LC fed mice. 
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We found that the LC significantly reduced the number of intersections and the length of 
processes compared to the normal-diet fed GFAP-IL6 mice. (Fig 37 A-H).  
We performed the bivariate correlation of morphological characteristics with overall astroglial 
cell size to investigate the impact of the size of astroglial cells on the structural parameters. We 
observed some positive correlation of the astroglial cell size with some of the morphological 
parameters. The data revealed that the convex perimeter, dendritic length and the number of 
nodes increased significantly with the overall increase in the entire cell structure (Fig 38 A-H, 
Table 15). 
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Figure 36. Effect of LC curcumin on astrocytes morphology in the hippocampus. (A) 3D reconstruction of 
astrocytes in wild type and GFAP-IL6 in both treated and non-treated mice Scale bar 10µm. (B-H) Graphs showing 
the morphological changes in Iba-1+ microglia. Two-way ANOVA, Tukey’s post-test, mean ± SEM) 
 
 
 
Fig 37. LC increased the ramification of astrocytes in the hippocampus region. (A-F) A Sholl analysis confirmed a significant 
decrease in a number of intersections and processes length in LC fed GFAP-IL6 mice compared to normal food-fed GFAP-IL6. 
Whereas, there were no significant changes occurred in wild type fed mice. LC significantly affects the inflamed astrocytes, which 
is observed in the peaks of the distributions of different morphological features being closer to the center compared to normal food-
fed GFAP-IL6 mice, we call it X at Ymax. Two-way ANOVA test. 
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Figure 38. Bivariate correlation: Effect of LC  on astrocytes morphology in the hippocampus. (A-F) Different 
morphological parameters have been plotted against the convex hull area to see the bivariate correlation between WT normal-
diet, WT LC-diet GFAP-IL6 normal-diet, and GFAP-IL6 LC-diet. 
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Table 14. Morphological analysis of GFAP+ astrocytes in the hippocampus 
 
 
 
 
 
Table 15. Bivariate correlation of morphological characteristics with overall astroglial cell 
size in the hippocampus 
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4.4.3. Summary 
 
In the present study, we have investigated some of the changes between ramified and non-
ramifies microglia which is consistent with the previous reports. In the hippocampus, Iba-1+ 
microglial cells of GFAP-IL6 mice normal fed had significantly larger soma areas, small convex 
areas, and convex perimeter than those of WT. The LC significantly increased the dendritic 
length and number of nodes than that of GFAP-IL6 normal fed mice. Whereas, in the cerebellum, 
Iba-1+ microglial cells of GFAP-IL6 mice normal fed had significantly large soma area, soma 
perimeter, and small convex area, convex perimeter than those of the wild type non-fed mice. 
The LC significantly reduced soma area, soma perimeter and number of nodes Iba-1+ microglial 
cells of GFAP-IL6 LC fed mice than that of GFAP-IL6 normal fed mice.  
Herein, morphological assessment of astrocytes in the hippocampus have shown that GFAP-IL6 
normal-diet mice had a significantly larger dendritic length, a number of processes, convex area, 
convex perimeter and a number of nodes compared to the wild types. The LC diet significantly 
decreased the dendritic length number of processes, convex area, convex perimeter and number 
of nodes.  
This study has investigated the impact of one of the curcumin formulation LC, against glial cell 
activation and chronic neuroinflammation. This study has provided a clue that LC has the 
potential to reduce and over-activation of microglia and astrocytes in the brain.   
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    5. General Discussion 
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Chronic neuroinflammation is considered one of the major contributing factors in the progression 
of various neurodegenerative diseases. Chronic microglial and astroglial activation is a 
prominent feature of chronic neuroinflammation (Gyengesi et al. 2019). The neurons are 
surrounded by microglial cells in the brain. During neuroinflammation, the neurons get damaged 
and secrete various factors which activate the microglia to rescue neurons by upregulating 
phagocytosis and production of an anti-oxidant enzyme (Suzumura 2013). Few studies have 
claimed that chronic neuroinflammation may be an initiator in the cascade of events leading to 
the deficit in neuronal function which defines the disease (Lynch 2010), A study performed in 
hypoxia, ischemia and lipopolysaccharide (HIL) mouse model have reported the neuronal death 
induced in neuroinflammation. The HIL induce the neuronal injury within the hippocampus, 
periventricular white matter, and neocortex of mouse brain which further lead to neuronal death, 
enhanced HIF-1α expression, and numerous Iba-1 labelled, activated microglia. Rapamycin 
treatment significantly reduced neuronal death and neuroinflammation (Srivastava et al. 2016). 
Another study performed in hAPP-J20 AD mouse model by studying disease pathology at four 
different age points 6, 12, 24 and 36 weeks using stereological methods. The study has 
investigated that there is no neuron loss in the hippocampal CA3 region at any age and the extent 
of neuron loss increases with age with the number of activated microglia. However loss of 
neurons from the hippocampal CA1 region begins as early as 12 weeks of age, which suggest 
that the neuronal death and neuroinflammation are the key factors in various neurodegenerative 
diseases (Wright et al. 2013), Furthermore, a study performed in patients with Multiple scleroses 
to investigate the neuroinflammation and neuronal pathology, Chronic neuroinflammation 
followed by an axonal pathological features, correlating with the number of infiltrating immune 
cells, and focal cortical thinning seen on magnetic resonance imaging, indicating complete tissue 
loss and death of neuronal cell bodies (Peterson et al. 2001). These evidence suggest that 
neuroinflammation has a key impact on neuronal functions and neuronal survival. 
 
In the present study, two different sets of groups were created, which were divided further into 
sub-cohorts for two different types of curcumin formulations. The two curcumin formulations 
MCP and LC have been fed to GFAP-IL6 mice for one month and six-months respectively in 
order to investigate the impact of these drugs on chronic neuroinflammation. In the case of MCP, 
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six cohorts were made and four cohorts were fed with different doses of MCP whereas; In the 
case of LC, four cohorts were made and only one dose of LC was fed to WT and GFAP-IL6 
cohorts. We have applied an array of experimental methods, including immunohistochemistry on 
the brain, combined with stereology and morphological analysis to investigate the effects of 
these curcumin formulations. 
Our results show that the number of Iba-1+ microglia is significantly higher in the cerebellum 
and hippocampus of the brain in GFAP-IL6 normal fed mice compared to the WT normal fed 
mice in both age groups. Firstly, WT and GFAP-IL6 non-fed cohorts in these two age groups 
were compared. It was observed from the comparative analysis that the WTs in both age groups 
have very similar Iba-1+ microglia, TSPO+ microglia, and GFAP+ astrocyte population numbers, 
with no significant differences. Similarly, the Iba-1+ microglia in both the hippocampus and 
cerebellum and TSPO+ microglia in the cerebellum in GFAP-IL6 groups in both age groups were 
similar. A previous study published by our group has estimated the number of TSPO+ cells in 
two age groups for 8 months and 18 months. The study reported that the TSPO+ cells in the 18 
months age group has a significantly high number of TSPO+ cells in the hippocampus whereas, 
the TSPO+ cells in both age groups have a nearly close number in cerebellum region (Gyengesi 
et al. 2018) . In this study, TSPO+ microglia in the cerebellum of the 4 month old group were 
significantly lower compared to the 8 month old group. Furthermore, GFAP+ astrocytes in the 
hippocampus were significantly higher in 4 months old GFAP-IL6 mice compared to the 8 
month cohort. The literature study has very limited information regarding the GFAP positive 
astrocytes. Some studies have suggested that aging in rodents brains show progressive increases 
in the levels of glial fibrillary acidic protein (GFAP) protein (Yoshida et al. 1996)   Gyengesi et 
al have investigated the astrocytes number by measuring the GFAP positive cells intensity 
analysis. Intensity analysis for GFAP positive cells showed that GFAPIL6 mice had a significant 
increase in GFAP intensity in both age groups, while the cerebellum had a more prominent 
increase compared with the hippocampus (Gyengesi et al. 2018).  
The high and medium doses of MCP significantly reduced the number of Iba-1+ microglia in the 
cerebellum and the hippocampus, with the high dose of MCP resulting in the most significant 
decrease. Feeding LC significantly decreased the Iba1+ microglia numbers by 25.88% in the 
hippocampus and by 48% in the cerebellum. Our results show a similar trend to a previous study 
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conducted in a mouse model of Alzheimer’s disease (human APP and PSEN1 transgenes mice), 
that have compared the effect of solid lipid curcumin formulation (SLCP) and normal curcumin 
(Maiti, Paladugu, and Dunbar 2018). They reported that the SLCP leads to a greater reduction in 
Iba-1+ microglial cells compared to the normal curcumin (Maiti, Paladugu, and Dunbar 2018). 
Previous studies have reported that the numbers of Iba-1+ microglia in the mouse brain increase 
in chronic neuroinflammatory conditions, which were significantly reduced after being treated 
with anti-inflammatory drugs such as Tenilsetam and dexamethasone (Gyengesi et al. 2018; 
Claessens et al. 2012). A recent study conducted in a mouse model of AD has reported the 
protective effect of a curcumin formulation. These studies used Image-J software to count the 
number of the Iba-1+ cell and reported that a solid lipid curcumin formulation was able to 
significantly downregulate the microglial numbers in different regions of the hippocampus in the 
mice brain (Maiti, Paladugu, and Dunbar 2018). Similarly, they claimed that the solid lipid 
curcumin has high permeability and potential effects against amyloid plaques relative to the 
normal curcumin (Maiti, Paladugu, and Dunbar 2018).   
Microglia, as the brain immune macrophages, has a surveillance function characterized by the 
continuous scanning of their surrounding microenvironment in a ramified morphology 
(Nimmerjahn, Kirchhoff, and Helmchen 2005; Davalos et al. 2005). Resting and non-activated 
microglia are thought to rest in a dormant state, whereas, when activated, the microglia are then 
associated with structural changes (Nolte et al. 1996). A previous study performed in healthy 
adult mice has reported that ramified cells have small somas, long and thin processes, necessary 
for active surveillance of microglia microdomains (Lawson et al. 1990). However, microglial 
cells are activated in response to the neuronal assault, injury or inflammation, and undergo 
morphological transformations (Nimmerjahn, Kirchhoff, and Helmchen 2005). A recent study 
performed in a mouse model of AD  has proved that curcumin can reduce the aggregation and 
de-ramification of microglial cells in the hippocampus (Maiti, Paladugu, and Dunbar 2018). 
Ramified microglia function in a highly dynamic manner, constantly surveying the neuronal 
environment for homeostatic and infective changes and protects hippocampal neurons under 
pathological conditions (Vinet et al. 2012). It has been reported that microglial cells are activated 
in response to many types of neuronal injury or inflammation, and undergo morphological 
transformations (Nimmerjahn, Kirchhoff, and Helmchen 2005). Moreover, resting microglia has 
the ability to facilitate prompt reactions to brain injury (Nolte et al. 1996). Studies have shown 
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that changes in microglial cell size can influence the entire morphology in response to different 
challenges to the CNS (Hinwood et al. 2013). A recent study conducted in mice has proved that 
curcumin can reduce the aggregation and de-ramification of microglial cells in the hippocampus. 
They reported that the microglia were more aggregated in the vehicle-treated group while, after 
injecting solid lipid curcumin to the mice for five days, they noticed a significant reduction in 
microglial aggregation, activation, and branches number (Maiti, Paladugu, and Dunbar 2018). In 
this study, microglial cells were reconstructed and quantitatively analyzed for changes in their 
morphology. It has been reported that microglial cells are activated in response to many types of 
neuronal injury or inflammation, and undergo morphological transformations (Nimmerjahn, 
Kirchhoff, and Helmchen 2005). Our results revealed that chronic neuroinflammation increased 
the aggregation and de-ramification of microglial cells and hypertrophy of astrocytes in GFAP-
IL6 mice. The literature studies have very limited evidence about the specific mechanism of the 
morphological changes occurred in microglial cells in chronic neuroinflammation. In this study, 
the microglial soma area and soma perimeter significantly increased in both the hippocampus 
and cerebellum of GFAP-IL6 mice compared to those of the healthy ones. Additionally, there 
were a significantly larger number of processes in microglia of the inflamed brains compared to 
normal brains. While in the case of LC, Iba-1+ microglial cells of GFAP-IL6 mice normal fed 
had significantly larger soma areas, small convex areas, and convex perimeter than those of WT. 
A recent study conducted in mice has showed that curcumin formulation can reduce the 
aggregation and de-ramification of microglial cells in the hippocampus. They reported that the 
microglia were more aggregated in the vehicle-treated group while, after injecting solid lipid 
curcumin to the mice for five days, they noticed a significant reduction in microglial aggregation, 
activation, and branches number (Maiti, Paladugu, and Dunbar 2018). Our results indicated that 
the high dose MCP significantly reduced the soma area and soma perimeter, while it 
significantly increased the number of nodes in the hippocampus. In the cerebellum, the high dose 
MCP significantly reduced the soma area and soma perimeter while it increased the convex area, 
convex perimeter, and dendritic length compared to the non-fed control. Interestingly, the 
morphology of microglia in the 140mg NC, GFAPIL6 mice was also affected, as soma area and 
soma perimeter was significantly decreased in the cerebellum of GFAP-IL6 mice. In short, the 
MCP modified microglia morphology towards that of in the normal mice. Whereas, The LC 
significantly increased the dendritic length and number of nodes than that of GFAP-IL6 normal 
116 
 
fed mice in the hippocampus and significantly reduced soma area, soma perimeter and more 
number of nodes Iba-1+ microglial cells of GFAP-IL6 LC fed mice than that of GFAP-IL6 
normal fed mice in the cerebellum.  
The previous research study had mentioned that microglial size has an impact on the overall 
cellular morphology (Raivich 2005). One of the studies performed in rats has correlated the 
microglial cells with total processes length, branch point, and total branch volume. They found 
that larger cells tended to have larger, thicker and more branches (Kongsui et al. 2014). In the 
present study, the correlation analysis revealed some significant correlations. In the 
hippocampus, microglial cells of WT and 70 mg/kg fed groups tended to increase the size of the 
soma area and convex perimeter of the microglia of each cohort with the increasing size of the 
cells. Whereas, the dendritic length of the microglia of the fed cohorts were increased with the 
overall cell size. While, in the cerebellum, it showed that the soma area and dendritic length of 
the microglia changed with the overall cell size, while the convex perimeter increased with the 
overall increase in microglial cells. In case of LC, in the hippocampus, correlation analysis of 
overall microglial cell size with each morphological characteristic revealed that the microglial 
cells of the GFAP-IL6 LC fed mice potentially increased the overall soma size and dendrites 
number. In addition, the convex perimeter and dendritic length of each cohort increased with the 
increasing size of the entire cell. In the cerebellum, it shows that the convex perimeter and the 
length of dendrites increased with the overall increase in microglial cells and numbers of nodes 
in GFAP-IL6 non fed cohorts were increased with the overall increase in microglial cells.  
The unique microglial morphology in human brains is more challenging. Postmortem studies 
have confirmed the existence of various morphological phenotypes (Sheng, Mrak, and Griffin 
1997). Recent advances in neuroimaging techniques have made it possible to visualize microglial 
activation by positron emission tomography (PET) (Banati 2002). Using this approach, the 
presence of activated microglia has been reported in the brains of humans who suffer from brain 
disorders such as Alzheimer's disease and Parkinson's disease (Cagnin et al. 2001). There are a 
still much gap and the lack of detailed knowledge on the fine properties of microglia in the 
human brain, and how these properties could be compared to those of rodents. A study 
conducted on human brains having died with no history of inflammatory. The study found 
different microglial phenotypes in postmortem samples of the dorsal anterior cingulate cortex 
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(dACC) (Miller et al. 2013). One interesting finding emerged from this analysis is to relate to 
mouse and human microglia. One of the studies conducted on human microglia has reported 
ramified microglia in the human prefrontal cortex have an average 5.8 (±0.5) primary processes 
(Torres-Platas et al. 2014) and we have identified that there are around 5.06 (±0.30) in mice 
(Table 10), which turned out to be comparable. 
TSPO exists in the outer mitochondrial membrane of the cell and it plays important roles in cell 
physiology (Papadopoulos et al. 1997). It has been reported in the literature studies that TSPO  
protein is expressed in microglia, astrocytes and at low levels in neurons in diseased brains 
(Cosenza-Nashat et al. 2009). In a study conducted in mice, it has been reported that the 
fluorescence intensity and the number of TSPO+ per 0.1mm2, has elevated in the brain after 
exposure to an injury or inflammation  (Bonsack, Alleyne, and Sukumari-Ramesh 2016). 
Another study conducted in our group in the same mouse model found that the number of 
TSPO+ cells was increased in GFAP-IL6 mice and even more in drug (Tenilsetam) treated mice 
(Gyengesi et al. 2018). In the present study, we have investigated the TSPO+ microglia cells 
only based on their morphology. Our study found that the total estimated number of TSPO+ 
microglia cells was significantly larger in the GFAP-IL6 group than that of the WT group in the 
cerebellum and the hippocampus. In our study, the 140mg/kg of MCP significantly 
downregulated microglial cells number in GFAP-IL6 mice in both the hippocampus and the 
cerebellum compared to the non-fed group. While LC significantly reduced the TSPO+ microglia 
numbers by 31% in the cerebellum and 24.45% in the hippocampus. 
Like microglia, astrocytes are also activated in response to injury, trauma, neuroinflammation 
and various other CNS challenges. When activated, they adopt more bushy shape with an 
increase in their number and length of processes (Fawcett and Asher 1999; McGraw, Hiebert, 
and Steeves 2001; Sofroniew 2009). A study recently used curcumin formulation has reported 
that curcumin treatment has decreased the astrocyte activation (Maiti, Paladugu, and Dunbar 
2018). Astrocytes are activated in response to neuroinflammation or injury. A study performed in 
a mouse model of Alzheimer’s disease has reported inhibition of GFAP+ astrocytes after being 
treated with curcumin and SLCP (Maiti, Paladugu, and Dunbar 2018). In our study, a 
significantly higher number of GFAP+ astrocytes have been observed in GFAP-IL6 mice 
compared to WT mice in the hippocampus. All three doses of MCP significantly decreased the 
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number of reactive astrocytes in the hippocampus compared to the GPAP-IL6 control mice 
whereas, in the LC fed GFAP-IL6 mice, a significant reduction in GFAP+ astrocytes were 
observed by 30% compared to the GFAP-IL6 normal food fed mice. 
Astrocytes, as a part of the anti-inflammatory response, are also activated in response to injury, 
trauma, neuroinflammation and various other CNS challenges and adopt more bushy shape with 
an increase in their number and length of processes, when activated (Fawcett and Asher 1999; 
McGraw, Hiebert, and Steeves 2001; Sofroniew 2009). Once they are activated, the reactive 
astrocytes undergo morphological changes relative to the resting cells, wherein cellular processes 
extend (Wilhelmsson et al. 2006; Grosche et al. 1999). In the MCP case, morphological 
investigations of astrocytes in the hippocampus have shown that astrocytes of GFAP-IL6 mice 
have significantly longer dendritic length and convex area compared to that of WT mice cells. 
While, in LC case, GFAP-IL6 normal-diet mice had a significantly larger dendritic length, a 
number of processes, convex area, convex perimeter and a number of nodes compared to the 
wild types. A study conducted in rat injury models has reported a decrease in hypertrophy of 
astrocytes after been treated with curcumin formulations (Ji et al. 2013; Maiti, Paladugu, and 
Dunbar 2018). Therefore, high dose MCP has significantly reduced the dendritic length and 
convex area in GFAP-IL6 fed mice compared to the normal fed GFAP-IL6 mice. While, The LC 
diet significantly decreased the dendritic length number of processes, convex area, convex 
perimeter and number of nodes.  
Furthermore, the bivariate correlations of morphological characteristics were performed with 
overall astroglial cell size to investigate the impact of the size of astroglial cells on the structural 
parameters. In MCP, it was observed that the number of nodes in the astrocytes of 35mg/kg and 
140mg/kg fed cohorts decreased when the overall size of the astrocytes decreased. In the case of 
primary dendrites, both the 70mg/kg and 140mg/kg doses positively decreased them with the 
decrease in the overall cell size of astrocytes. This clearly showed that the 140mg MCP decrease 
the astrocytes activation and reduced its size like the astrocytes in the WT. Whereas, we 
observed some positive correlation of the astroglial cell size with the some of the morphological 
parameters, which revealed that the convex perimeter, dendritic length and the number of nodes 
increased significantly with the overall increase in the entire cell structure 
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In summary, our study has investigated that, the MCP short term feeding at a reasonable dose 
(highest dose: 140mg/kg bw, approx. 12mg/kg bw in humans) is able to significantly 
downregulate the chronic neuroinflammation in the GFAP-IL6 measured by various anatomical 
markers, which could be translated into human studies with patients with neuroinflammatory 
disorders. Whereas, long term feeding of LC (Dose: 500ppm, approx. 3.5mg/kg bw in humans) 
has the potential to reduce the chronic neuroinflammation and over-activation of microglia and 
astrocytes in the brain. 
This study has investigated that, the MCP at a reasonable dose (highest dose: 140mg/kg bw, 
approx. 12mg/kg bw in humans) and LC (500ppm~60mg/kg bw, approx. 5.5mg/kg bw in 
humans) is able to significantly downregulate the microglial and astroglial activation in the 
GFAP-IL6 measured by various anatomical markers. It also has investigated that both 
formulations of curcumin have the potential to reverse the activation of microglial and astrocytes 
measured through morphological tools. Altogether this study did both answered some questions 
and opened a new window of possibilities in order to ameliorate the chronic neuroinflammation 
symptoms caused by over-activation of microglia and astrocytes in the brain.  
Our results might also have clinical relevance if translated into human studies in patients with 
neuroinflammatory disorders following the progress of their treatment with curcumin using 
different imaging techniques such as PET imaging with TSPO ligands (Dupont et al. 2017). 
There are a number of curcumin formulations tested in human patients and volunteers to 
investigate its effects against chronic inflammation conditions. Curcumin C3 complex® (Sabinsa 
Corporation Piscataway, NJ, USA) is a curcumin formulation. In a study, this formulation was 
taken by patients with mild AD on 2 and 4 gm/day for 24-weeks to two different groups. No 
differences were detected between treatment groups and placebo due to the low bioavailability of 
the curcumin as the likely reason (Ringman et al. 2012). The major challenges to the therapeutic 
potential of curcumin, which are identified as a potential limitation in most CNS disorders, are 
its poor bioavailability and BBB permeability, therefore, controlled formulation of curcumin is 
required for effective therapeutic outcomes. In a study, preclinical investigations have been 
conducted in 60 healthy adults aged 60-85. This  double-blind, randomized, placebo-
controlled trial examined the acute (1 and 3 h after a single dose), chronic (4 weeks) and acute-
on-chronic (1 and 3 h after single dose following chronic treatment) effects of solid 
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lipid curcumin formulation (400 mg as Longvida®) on cognitive function, mood and blood 
biomarkers in 60 healthy adults aged 60-85. The study has proved that curcumin significantly 
improved performance, memory, and mood compared with placebo in healthy human subjects 
(Cox, Pipingas, and Scholey 2015). Few studies have been performed in patients with 
Alzheimer’s disease. Baum et al. (Baum et al. 2008) conducted a randomized, double-blind, 
placebo-controlled study 34 patients with Alzheimer’s disease. Two different doses of curcumin 
mixed with food (1 g/day or 4 g/day) or placebo (4 g/day) were received by each subject for six 
months the Mini-Mental State Examination (MMSE) score change was measured between the 
baseline and the follow-up assessment. The authors did not observe any significant difference 
between curcumin and placebo and no reduction in serum A𝛽40 levels were observed (Baum et 
al. 2008). Another double-blind, placebo-controlled was conducted in 36 patients with dementia 
which randomly received two different doses of Curcumin C3 Complex in two divided doses or 
placebo for 24 weeks which was extended to 48 weeks. The authors have stated some outcomes 
that the patients become better and a change at the Neuropsychiatric Inventory (NPI), the 
Alzheimer’s disease Cooperative Study Activities of Daily Living (ADCS-ADL), and the MMSE 
were observed (Ringman et al. 2012). Another study conducted in 2012, has reported that three 
dementia patients treated with 100 mg/day of curcumin for 12 weeks reprted a decreased in NPI-
questionnaire brief version (NPI-Q) score (particularly, reduction in agitation, irritability, 
anxiety, and apathy) (Hishikawa et al. 2012). Similarly, there are several ongoing clinical trials 
evaluating the efficacy of curcumin in AD patients and neuroinflammatory conditions with the 
Australian and New Zealand clinical trial (ANZCTR). According to ANZCTR, In Australia, a 
randomized double-blind placebo controlled trial has been started and is recruiting patients with 
dementia (sample size: 200) which will be treated with oral curcumin titrated up to 1500 mg/day. 
The expected outcome is the prevention of the cognitive decline in the curcumin treated group. 
Similarly, the two curcumin formulations used in this study have very positive outcomes in 
mouse models and these preparations could be used in diseases with neuroinflammatory 
responses in human patients in the future. 
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Our study have reported some of the key investigations but some limitations of this study are 
there. In future, gene expression profiles study using RNA sequencing, flow cytometry, and the 
curcumin concentration in the brain would give some more understanding about the exact 
mechanism and effects of curcumin against neuroinflammation. Few studies in the literature 
have investigated the gene expression profiles in order to reveal the microglial or even astroglial 
activation. A study performed in transgenic mice expressing eGFP in CNS resident microglia 
and peripheral monocytes (CX3CR1+/GFP) with spinal card injury (SCI). The study has 
investigated the molecular alterations in microglia, the potential involvement of DNA damage, 
the upregulation of tumor suppressor gene breast cancer susceptibility gene 1 (Brca1) in 
microglia and increased expression of microglia and monocyte markers after SCI and 
neuroinflammation (Noristani et al. 2017). The same study has also used flow cytometry to study 
neuroinflammation after injury and reported eGFP high expressing cells (Noristani et al. 2017). 
Another study has shown that ramified microglia express CD11b+/CD45low cells whereas fully 
activated microglia and infiltrating macrophages are CD11b+/CD45high cells using flow 
cytometry (David and Kroner 2011). Similarly, a study conducted in aged C57BL/6J mice and 
mice lacking the microglial-secreted cytokines (IL-1α, TNF, and C1q) known to induce astrocyte 
activation have reported that the astrocytes gene is activated during aging and neuroinflammation 
which leads to astrocytes activation (Clarke et al. 2018). The difference in protein expression is 
difficult to reliably quantify histologically, but rather more accurate when microglia and 
macrophages are isolated from CNS tissue and analysed by flow cytometric.  A study has 
discovered that in contrast to peripheral macrophages, parenchymal microglia expressed much 
lower levels of CD45, a protein tyrosine phosphatase expressed by all nucleated cells of 
hemopoietic lineage (Carson, Thrash, and Walter 2006). A cell-specific flow cytometry and gene 
expression study were performed in the Superoxide Dismutase 1 (SOD1)G93A transgenic mouse 
model of ALS. The study showed significant phenotypic changes in microglia and the expression 
of genes linked to neuroprotection and neuroinflammation (Chiu et al. 2008).In the future, it 
could be possible to determine the exact concentration of curcumin and its derivatives and 
metabolites in the brain. Moreover, the beneficial effects of MCP and LC on impairment in 
cognition and motor performance of GFAP-IL6 mice would be a worthwhile investigation. 
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